BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 617] [Article Influence: 109.5] [Reference Citation Analysis]
Number Citing Articles
1 Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 2020; 159: 335-349. e15. [PMID: 32247694 DOI: 10.1053/j.gastro.2020.02.068] [Cited by in Crossref: 123] [Cited by in F6Publishing: 123] [Article Influence: 61.5] [Reference Citation Analysis]
2 Delgado JA, Ballesteros MA, Parera MM, Bauça JM. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers. Lab Med 2021:lmab016. [PMID: 33900408 DOI: 10.1093/labmed/lmab016] [Reference Citation Analysis]
3 Huang D, Zhang X, Zhao C, Fu X, Zhang W, Kong W, Zhang B, Zhao Y. Ultrasound‐Responsive Microfluidic Microbubbles for Combination Tumor Treatment. Adv Therap 2021;4:2100050. [DOI: 10.1002/adtp.202100050] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Guha Majumdar A, Subramanian M. Hydroxychavicol from Piper betle induces apoptosis, cell cycle arrest, and inhibits epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Pharmacol 2019;166:274-91. [PMID: 31154000 DOI: 10.1016/j.bcp.2019.05.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Chiou SH, Dorsch M, Kusch E, Naranjo S, Kozak MM, Koong AC, Winslow MM, Grüner BM. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 2018;8:14008. [PMID: 30228296 DOI: 10.1038/s41598-018-32159-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chen X, Tao Y, He M, Deng M, Guo R, Sheng Q, Wang X, Ren K, Li T, He X, Zang S, Zhang Z, Li M, He Q. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Theranostics 2021;11:8692-705. [PMID: 34522207 DOI: 10.7150/thno.60437] [Reference Citation Analysis]
7 Gupta P, Pérez-Mancera PA, Kocher H, Nisbet A, Schettino G, Velliou EG. A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the in vivo Tumor Microenvironment. Front Bioeng Biotechnol 2020;8:290. [PMID: 32391339 DOI: 10.3389/fbioe.2020.00290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
8 Totti S, Vernardis SI, Meira L, Pérez-mancera PA, Costello E, Greenhalf W, Palmer D, Neoptolemos J, Mantalaris A, Velliou EG. Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. Drug Discovery Today 2017;22:690-701. [DOI: 10.1016/j.drudis.2017.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
9 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Reference Citation Analysis]
10 Shan YS, Chen LT, Wu JS, Chang YF, Lee CT, Wu CH, Chiang NJ, Huang HE, Yen CJ, Chao YJ, Tsai HJ, Chen CY, Kang JW, Kuo CF, Tsai CR, Weng YL, Yang HC, Liu HC, Chang JS. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. J Biomed Sci 2020;27:69. [PMID: 32456644 DOI: 10.1186/s12929-020-00664-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open 2019;9:e028696. [PMID: 31434770 DOI: 10.1136/bmjopen-2018-028696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lin Q, Xiao G, Wang G, He Q, Xu L, Qiu P, Tan S, Gong M, Wen J, Xiao X. Heat Shock Factor 1 in Relation to Tumor Angiogenesis and Disease Progression in Patients With Pancreatic Cancer. Pancreas 2020;49:1327-34. [PMID: 33122521 DOI: 10.1097/MPA.0000000000001683] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kamyabi N, Abbasgholizadeh R, Maitra A, Ardekani A, Biswal SL, Grande-Allen KJ. Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. Biomed Microdevices 2020;22:23. [PMID: 32162067 DOI: 10.1007/s10544-020-00483-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
14 Won EJ, Park H, Chang SH, Kim JH, Kwon H, Cho YS, Yoon TJ. One-shot dual gene editing for drug-resistant pancreatic cancer therapy. Biomaterials 2021;279:121252. [PMID: 34781244 DOI: 10.1016/j.biomaterials.2021.121252] [Reference Citation Analysis]
15 Bahmani B, Uehara M, Ordikhani F, Li X, Jiang L, Banouni N, Ichimura T, Kasinath V, Eskandari SK, Annabi N, Bromberg JS, Shultz LD, Greiner DL, Abdi R. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery. EBioMedicine 2018;38:79-88. [PMID: 30497977 DOI: 10.1016/j.ebiom.2018.11.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
16 Holst S, Belo AI, Giovannetti E, van Die I, Wuhrer M. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. Sci Rep. 2017;7:16623. [PMID: 29192278 DOI: 10.1038/s41598-017-16811-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
17 Mesquita G, Prevarskaya N, Schwab A, Lehen'kyi V. Role of the TRP Channels in Pancreatic Ductal Adenocarcinoma Development and Progression. Cells 2021;10:1021. [PMID: 33925979 DOI: 10.3390/cells10051021] [Reference Citation Analysis]
18 Hafezi S, Saber-Ayad M, Abdel-Rahman WM. Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. Int J Mol Sci 2021;22:10219. [PMID: 34638560 DOI: 10.3390/ijms221910219] [Reference Citation Analysis]
19 Ren S, Chen X, Cui W, Chen R, Guo K, Zhang H, Chen S, Wang Z. Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. Cancer Manag Res 2019;11:7857-66. [PMID: 31686905 DOI: 10.2147/CMAR.S217033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mallangada NA, Vargas JM, Thomas S, DiGiovanni MG, Vaeth BM, Nemesure MD, Wang R, LaComb JF, Williams JL, Golub LM, Johnson F, Mackenzie GG. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Mol Carcinog 2018;57:1130-43. [PMID: 29683208 DOI: 10.1002/mc.22830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Sasaki N, Gomi F, Yoshimura H, Yamamoto M, Matsuda Y, Michishita M, Hatakeyama H, Kawano Y, Toyoda M, Korc M, Ishiwata T. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer. Cancers (Basel) 2020;12:E2976. [PMID: 33066597 DOI: 10.3390/cancers12102976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Seo MS, Yeo J, Hwang IC, Shim JY. Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis. Clin Rheumatol. 2019;38:3109-3116. [PMID: 31270697 DOI: 10.1007/s10067-019-04660-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Aguilera KY, Dawson DW. WNT Ligand Dependencies in Pancreatic Cancer. Front Cell Dev Biol 2021;9:671022. [PMID: 33996827 DOI: 10.3389/fcell.2021.671022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Maharaj AD, Samoborec S, Evans SM, Zalcberg J, Neale RE, Goldstein D, Merrett N, White K, Croagh D, Pilgrim CH, Evans P, Knowles B, Leong T, Philip J, Smith M, Ioannou L. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. HPB 2020;22:187-203. [DOI: 10.1016/j.hpb.2019.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
25 Skaro M, Nanda N, Gauthier C, Felsenstein M, Jiang Z, Qiu M, Shindo K, Yu J, Hutchings D, Javed AA, Beckman R, He J, Wolfgang CL, Thompson E, Hruban RH, Klein AP, Goggins M, Wood LD, Roberts NJ. Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology 2019;156:1905-13. [PMID: 30716324 DOI: 10.1053/j.gastro.2019.01.254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
26 Wang CJ, Li X, Shi P, Ding HY, Liu YP, Li T, Lin PP, Wang YS, Zhang GQ, Cao Y. Holliday junction recognition protein promotes pancreatic cancer growth and metastasis via modulation of the MDM2/p53 signaling. Cell Death Dis 2020;11:386. [PMID: 32439850 DOI: 10.1038/s41419-020-2595-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sagami R, Yamao K, Nakahodo J, Minami R, Tsurusaki M, Murakami K, Amano Y. Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma. Cancers (Basel) 2021;13:945. [PMID: 33668239 DOI: 10.3390/cancers13050945] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Fanchon LM, Russell J, Pillarsetty N, O'Donoghue I, Gangangari K, Yu KH, Humm JL. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One 2020;15:e0231745. [PMID: 32298392 DOI: 10.1371/journal.pone.0231745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol 2019;16:11-26. [PMID: 30341417 DOI: 10.1038/s41571-018-0112-1] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 55.0] [Reference Citation Analysis]
30 Sakai A, Masuda A, Eguchi T, Anami T, Nishi K, Furumatsu K, Okabe Y, Kakuyama S, Sato Y, Nishioka C, Sanuki T, Yagi Y, Kobayashi T, Shiomi H, Kodama Y. Clinical outcome of conservatively managed pancreatic intraductal papillary mucinous neoplasms with mural nodules and main duct dilation. J Gastroenterol 2021;56:285-92. [PMID: 33112991 DOI: 10.1007/s00535-020-01739-y] [Reference Citation Analysis]
31 Takagi K, Imura J, Shimomura A, Noguchi A, Minamisaka T, Tanaka S, Nishida T, Hatta H, Nakajima T. Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. Oncol Lett 2020;20:2888-96. [PMID: 32782605 DOI: 10.3892/ol.2020.11825] [Reference Citation Analysis]
32 Vaes RDW, van Dijk DPJ, Welbers TTJ, Blok MJ, Aberle MR, Heij L, Boj SF, Olde Damink SWM, Rensen SS. Generation and initial characterization of novel tumour organoid models to study human pancreatic cancer-induced cachexia. J Cachexia Sarcopenia Muscle 2020;11:1509-24. [PMID: 33047901 DOI: 10.1002/jcsm.12627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Mouratidis PXE, Costa M, Rivens I, Repasky EE, Ter Haar G. Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. J R Soc Interface 2021;18:20210266. [PMID: 34229458 DOI: 10.1098/rsif.2021.0266] [Reference Citation Analysis]
34 Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, Liu LM. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Front Cell Dev Biol 2021;9:641836. [PMID: 33855021 DOI: 10.3389/fcell.2021.641836] [Reference Citation Analysis]
35 Morimachi M, Hirabayashi K, Takanashi Y, Kawanishi A, Saika T, Ueyama Y, Nakagohri T, Nakamura N, Suzuki H, Kagawa T. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. J Clin Pathol 2020:jclinpath-2020-207002. [PMID: 33097588 DOI: 10.1136/jclinpath-2020-207002] [Reference Citation Analysis]
36 Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18:295-304. [PMID: 29334794 DOI: 10.1080/14737140.2018.1428093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
37 Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Büchler MW, Neoptolemos JP. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Journal of Pancreatology 2020;3:1-11. [DOI: 10.1097/jp9.0000000000000040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
38 Wang M, Li Y, Wang M, Liu K, Hoover AR, Li M, Towner RA, Mukherjee P, Zhou F, Qu J, Chen WR. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomater 2021:S1742-7061(21)00716-9. [PMID: 34757232 DOI: 10.1016/j.actbio.2021.10.048] [Reference Citation Analysis]
39 Ritchie S, Pereira BA, Vennin C, Timpson P. Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation. Expert Opin Ther Targets 2020;24:171-4. [PMID: 32031028 DOI: 10.1080/14728222.2020.1727887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Cascioferro S, Li Petri G, Parrino B, El Hassouni B, Carbone D, Arizza V, Perricone U, Padova A, Funel N, Peters GJ, Cirrincione G, Giovannetti E, Diana P. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Molecules 2020;25:E329. [PMID: 31947550 DOI: 10.3390/molecules25020329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
41 Tuntithavornwat S, Shea DJ, Wong BS, Guardia T, Lee SJ, Yankaskas CL, Zheng L, Kontrogianni-Konstantopoulos A, Konstantopoulos K. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. Cancer Lett 2022;526:155-67. [PMID: 34826548 DOI: 10.1016/j.canlet.2021.11.016] [Reference Citation Analysis]
42 Lu J, Wei S, Lou J, Yin S, Zhou L, Zhang W, Zheng S. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response. Med Sci Monit 2020;26:e925733. [PMID: 32706768 DOI: 10.12659/MSM.925733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhang J, Wang W, Zhou Y, Yang J, Xu J, Xu Z, Xu B, Yan L, Cheng XD, Li M, Qin JJ. Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice. Front Pharmacol 2020;11:457. [PMID: 32322210 DOI: 10.3389/fphar.2020.00457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
44 Qiu C, Yang L, Wang B, Cui L, Li C, Zhuo Y, Zhang L, Zhang S, Zhang Q, Wang X. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. Biomedicine & Pharmacotherapy 2019;115:108952. [DOI: 10.1016/j.biopha.2019.108952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
45 Shimomura H, Okada R, Tanaka T, Hozaka Y, Wada M, Moriya S, Idichi T, Kita Y, Kurahara H, Ohtsuka T, Seki N. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Int J Mol Sci 2020;21:E6459. [PMID: 32899691 DOI: 10.3390/ijms21186459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Nakao Y, Nakagawa S, Yamashita YI, Umezaki N, Okamoto Y, Ogata Y, Yasuda-Yoshihara N, Itoyama R, Yusa T, Yamashita K, Miyata T, Okabe H, Hayashi H, Imai K, Baba H. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Ann Surg Oncol 2021;28:4733-43. [PMID: 33393038 DOI: 10.1245/s10434-020-09383-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Brumskill S, Barrera LN, Calcraft P, Phillips C, Costello E. Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. J Physiol Biochem 2021. [PMID: 34865180 DOI: 10.1007/s13105-021-00857-2] [Reference Citation Analysis]
48 Sakhneny L, Khalifa-malka L, Landsman L. Pancreas organogenesis: Approaches to elucidate the role of epithelial-mesenchymal interactions. Seminars in Cell & Developmental Biology 2019;92:89-96. [DOI: 10.1016/j.semcdb.2018.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
49 Chen X, Jia F, Li Y, Deng Y, Huang Y, Liu W, Jin Q, Ji J. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. Biomaterials 2020;246:119999. [PMID: 32247201 DOI: 10.1016/j.biomaterials.2020.119999] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
50 Arteta AA, Sánchez-Jiménez M, Dávila DF, Palacios OG, Cardona-Castro N. Biliary Tract Carcinogenesis Model Based on Bile Metaproteomics. Front Oncol 2020;10:1032. [PMID: 32793466 DOI: 10.3389/fonc.2020.01032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kong B, Bruns P, Behler NA, Chang L, Schlitter AM, Cao J, Gewies A, Ruland J, Fritzsche S, Valkovskaya N, Jian Z, Regel I, Raulefs S, Irmler M, Beckers J, Friess H, Erkan M, Mueller NS, Roth S, Hackert T, Esposito I, Theis FJ, Kleeff J, Michalski CW. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. Gut 2018;67:146-56. [PMID: 27646934 DOI: 10.1136/gutjnl-2015-310913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
52 Zambirinis CP, Miller G. Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med 2017;23:465-81. [PMID: 28400243 DOI: 10.1016/j.molmed.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
53 Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020;19:1623-1635. [PMID: 32430484 DOI: 10.1158/1535-7163.mct-19-0997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Filippi R, Lombardi P, Depetris I, Fenocchio E, Quarà V, Chilà G, Aglietta M, Leone F. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opin Pharmacother 2018;19:1451-63. [PMID: 30161003 DOI: 10.1080/14656566.2018.1512585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Dong J, Yu J, Li Z, Gao S, Wang H, Yang S, Wu L, Lan C, Zhao T, Gao C, Liu Z, Wang X, Hao J. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. J Cachexia Sarcopenia Muscle 2021;12:704-16. [PMID: 33763996 DOI: 10.1002/jcsm.12692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Kirkegård J, Mortensen FV, Hansen CP, Mortensen MB, Sall M, Fristrup C. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Eur J Surg Oncol 2019;45:1901-5. [PMID: 31160135 DOI: 10.1016/j.ejso.2019.05.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
57 Minami F, Sasaki N, Shichi Y, Gomi F, Michishita M, Ohkusu-Tsukada K, Toyoda M, Takahashi K, Ishiwata T. Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures. Sci Rep 2021;11:6775. [PMID: 33762591 DOI: 10.1038/s41598-021-86028-1] [Reference Citation Analysis]
58 Jiang H, Wang S, Zhou X, Wang L, Ye L, Zhou Z, Tang J, Liu X, Teng L, Shen Y. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. J Control Release 2018;286:254-63. [PMID: 30075209 DOI: 10.1016/j.jconrel.2018.07.047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
59 Liu M, Yang J, Zhang Y, Zhou Z, Cui X, Zhang L, Fung KM, Zheng W, Allard FD, Yee EU, Ding K, Wu H, Liang Z, Zheng L, Fernandez-Zapico ME, Li YP, Bronze MS, Morris KT, Postier RG, Houchen CW, Yang J, Li M. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Clin Cancer Res 2018;24:3186-96. [PMID: 29615456 DOI: 10.1158/1078-0432.CCR-18-0263] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
60 Yang SZ, Xu F, Yuan K, Sun Y, Zhou T, Zhao X, McDonald JM, Chen Y. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation. Lab Invest 2020;100:777-85. [PMID: 31896813 DOI: 10.1038/s41374-019-0365-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Xu H, Sun J, Zhou L, Du QC, Zhu HY, Chen Y, Wang XY. Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer. World J Clin Cases 2021; 9(35): 10884-10898 [DOI: 10.12998/wjcc.v9.i35.10884] [Reference Citation Analysis]
62 Liu J, Kang R, Tang D. The Art of War: Ferroptosis and Pancreatic Cancer. Front Pharmacol 2021;12:773909. [PMID: 34955844 DOI: 10.3389/fphar.2021.773909] [Reference Citation Analysis]
63 Schneider C, Sodergren MH, Pencavel T, Soggiu F, Bhogal RH, Khan AZ. Prognostic relevance of the posterior resection margin for predicting disease free survival in ampullary adenocarcinoma. Surg Oncol 2020;35:211-7. [PMID: 32911213 DOI: 10.1016/j.suronc.2020.08.028] [Reference Citation Analysis]
64 Renelus BD, Jamorabo DS, Boston I, Briggs WM, Poneros JM. Endoscopic Ultrasound-Guided Fine Needle Biopsy Needles Provide Higher Diagnostic Yield Compared to Endoscopic Ultrasound-Guided Fine Needle Aspiration Needles When Sampling Solid Pancreatic Lesions: A Meta-Analysis. Clin Endosc 2021;54:261-8. [PMID: 32892519 DOI: 10.5946/ce.2020.101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Er JL, Goh PN, Lee CY, Tan YJ, Hii LW, Mai CW, Chung FF, Leong CO. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis 2018;23:343-55. [PMID: 29740790 DOI: 10.1007/s10495-018-1459-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
66 Momeny M, Alishahi Z, Eyvani H, Esmaeili F, Zaghal A, Ghaffari P, Tavakkoly-bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. Cell Oncol 2020;43:81-93. [DOI: 10.1007/s13402-019-00473-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
67 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
68 Mihaljevic A, Al-saeedi M, Hackert T. Pancreatic surgery: we need clear definitions. Langenbecks Arch Surg 2019;404:159-65. [DOI: 10.1007/s00423-018-1725-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Baenas DF, Miretti VS, Caeiro F, Paira S. Differential diagnosis between pancreatic involvement in IgG4-related disease and pancreatic cancer. Gastroenterol Hepatol 2021;44:144-55. [PMID: 32718841 DOI: 10.1016/j.gastrohep.2020.05.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. Cancer Treat Rev 2019;81:101926. [PMID: 31739115 DOI: 10.1016/j.ctrv.2019.101926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
71 Asahina K. Induction of Cell Death in Pancreatic Tumors by Zinc and Its Fluorescence Chelator TSQ. Biol Trace Elem Res 2021. [PMID: 34100198 DOI: 10.1007/s12011-021-02770-7] [Reference Citation Analysis]
72 Yeh C, Bates SE. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Semin Oncol 2021:S0093-7754(21)00001-4. [PMID: 33712267 DOI: 10.1053/j.seminoncol.2021.01.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas 2019;48:837-43. [PMID: 31210666 DOI: 10.1097/MPA.0000000000001345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
74 Lee W, Il An G, Park H, Sarkar S, Ha YS, Huynh PT, Bhise A, Bhatt N, Ahn H, Pandya DN, Kim JY, Kim S, Jun E, Kim SC, Lee KC, Yoo J. Imaging Strategy that Achieves Ultrahigh Contrast by Utilizing Differential Esterase Activity in Organs: Application in Early Detection of Pancreatic Cancer. ACS Nano 2021. [PMID: 34405675 DOI: 10.1021/acsnano.1c05165] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Liu XJ, Li L, Liu XJ, Li Y, Zhao CY, Wang RQ, Zhen YS. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma. Int J Nanomedicine 2017;12:5255-69. [PMID: 28769562 DOI: 10.2147/IJN.S139507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
76 Exarchakou A, Papacleovoulou G, Rous B, Magadi W, Rachet B, Neoptolemos JP, Coleman MP. Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study. Pancreatology 2020;20:454-61. [PMID: 32014435 DOI: 10.1016/j.pan.2020.01.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Baechle JJ, Marincola Smith P, Tan M, Solórzano CC, Lopez-Aguiar AG, Dillhoff M, Beal EW, Poultsides G, Makris E, Rocha FG, Crown A, Cho C, Beems M, Winslow ER, Rendell VR, Krasnick BA, Fields R, Maithel SK, Bailey CE, Idrees K. Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Ann Surg Oncol 2020;27:3915-23. [PMID: 32328982 DOI: 10.1245/s10434-020-08497-4] [Reference Citation Analysis]
78 Ma C, Cui Z, Wang Y, Zhang L, Wen J, Guo H, Li N, Zhang W. Bioinformatics analysis reveals TSPAN1 as a candidate biomarker of progression and prognosis in pancreatic cancer. Bosn J Basic Med Sci 2021;21:47-60. [PMID: 33188589 DOI: 10.17305/bjbms.2020.5096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lang C, Wang J, Chen L. CD25-expressing Th17 cells mediate CD8+ T cell suppression in CTLA-4 dependent mechanisms in pancreatic ductal adenocarcinoma. Exp Cell Res 2017;360:384-9. [PMID: 28942020 DOI: 10.1016/j.yexcr.2017.09.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
80 Jäkel C, Bergmann F, Toth R, Assenov Y, van der Duin D, Strobel O, Hank T, Klöppel G, Dorrell C, Grompe M, Moss J, Dor Y, Schirmacher P, Plass C, Popanda O, Schmezer P. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nat Commun 2017;8:1323. [PMID: 29109526 DOI: 10.1038/s41467-017-01118-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
81 Saluja A, Maitra A. Pancreatitis and Pancreatic Cancer. Gastroenterology 2019;156:1937-40. [DOI: 10.1053/j.gastro.2019.03.050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
82 Diaz-Riascos ZV, Ginesta MM, Fabregat J, Serrano T, Busquets J, Buscail L, Cordelier P, Capellá G. Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. Mol Ther Nucleic Acids 2019;17:491-503. [PMID: 31336236 DOI: 10.1016/j.omtn.2019.06.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
83 Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. The Lancet Gastroenterology & Hepatology 2018;3:413-23. [DOI: 10.1016/s2468-1253(18)30081-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
84 Gustavell T, Sundberg K, Langius-Eklöf A. Using an Interactive App for Symptom Reporting and Management Following Pancreatic Cancer Surgery to Facilitate Person-Centered Care: Descriptive Study. JMIR Mhealth Uhealth 2020;8:e17855. [PMID: 32554375 DOI: 10.2196/17855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Lee J, Lee J, Kim JH. Scattered DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine and paracrine signaling in metastatic pancreatic cancer. Cancer Lett 2019;456:1-12. [PMID: 30902562 DOI: 10.1016/j.canlet.2019.03.006] [Reference Citation Analysis]
86 Liu J, Kuang F, Kang R, Tang D. Alkaliptosis: a new weapon for cancer therapy. Cancer Gene Ther 2020;27:267-9. [DOI: 10.1038/s41417-019-0134-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
87 Tjomsland V, Aasrum M, Christoffersen T, Gladhaug IP. Functional heterogeneity in tumor-derived human pancreatic stellate cells: Differential expression of HGF and implications for mitogenic signaling and migration in pancreatic cancer cells. Oncotarget 2017;8:71672-84. [PMID: 29069737 DOI: 10.18632/oncotarget.17800] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
88 Barua R, Mizuno K, Tashima Y, Ogawa M, Takeuchi H, Taguchi A, Okajima T. Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers. Molecules 2021;26:882. [PMID: 33562410 DOI: 10.3390/molecules26040882] [Reference Citation Analysis]
89 Gough NR, Xiang X, Mishra L. TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. Gastroenterology 2021;161:434-452.e15. [PMID: 33940008 DOI: 10.1053/j.gastro.2021.04.064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Lee J, Lee J, Kim JH. Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer. Cell Oncol (Dordr) 2020;43:821-34. [PMID: 32483746 DOI: 10.1007/s13402-020-00527-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Nguyen L, Schilling D, Dobiasch S, Raulefs S, Santiago Franco M, Buschmann D, Pfaffl MW, Schmid TE, Combs SE. The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3703. [PMID: 33317198 DOI: 10.3390/cancers12123703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
93 El-Ashmawy NE, Al-Ashmawy GM, Hamouda SM. Long non-coding RNA FAM83H-AS1 as an emerging marker for diagnosis, prognosis and therapeutic targeting of cancer. Cell Biochem Funct 2021;39:350-6. [PMID: 33159470 DOI: 10.1002/cbf.3601] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer 2019;125:57-67. [PMID: 30457666 DOI: 10.1002/cncr.31787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
95 Pan H, Diao H, Zhong W, Wang T, Wen P, Wu C. A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis. Front Oncol 2021;11:656564. [PMID: 34055623 DOI: 10.3389/fonc.2021.656564] [Reference Citation Analysis]
96 Ren S, Zhao R, Zhang J, Guo K, Gu X, Duan S, Wang Z, Chen R. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Abdom Radiol 2020;45:1524-33. [DOI: 10.1007/s00261-020-02506-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
97 Zhang F, Zhong W, Li H, Huang K, Yu M, Liu Y. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front Cell Dev Biol 2021;9:665265. [PMID: 34124046 DOI: 10.3389/fcell.2021.665265] [Reference Citation Analysis]
98 Takhsha FS, Vangestel C, Tanc M, De Bruycker S, Berg M, Pintelon I, Stroobants S, De Meyer GRY, Van Der Veken P, Martinet W. ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:750259. [PMID: 34868951 DOI: 10.3389/fonc.2021.750259] [Reference Citation Analysis]
99 Manoharan D, Chang LC, Wang LC, Shan YS, Lin FC, Wu LC, Sheu HS, Su WP, Yeh CS. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-ray Dose Delivery to Pancreatic Tumors. ACS Nano 2021;15:9084-100. [PMID: 33974409 DOI: 10.1021/acsnano.1c02283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 James AD, Richardson DA, Oh IW, Sritangos P, Attard T, Barrett L, Bruce JIE. Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2). Br J Cancer 2020;122:266-78. [PMID: 31819190 DOI: 10.1038/s41416-019-0675-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
101 Huo Z, Zhai S, Weng Y, Qian H, Tang X, Shi Y, Deng X, Wang Y, Shen B. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Onco Targets Ther 2019;12:5037-51. [PMID: 31303762 DOI: 10.2147/OTT.S206039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
102 N B, Chandrashekar KR, Prabhu A, Rekha PD. Tetrandrine isolated from Cyclea peltata induces cytotoxicity and apoptosis through ROS and caspase pathways in breast and pancreatic cancer cells. In Vitro Cell Dev Biol Anim 2019;55:331-40. [PMID: 30945115 DOI: 10.1007/s11626-019-00332-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
103 Wang K, He H. Pancreatic Tumor Microenvironment. Adv Exp Med Biol 2020;1296:243-57. [PMID: 34185297 DOI: 10.1007/978-3-030-59038-3_15] [Reference Citation Analysis]
104 Samain R, Brunel A, Douché T, Fanjul M, Cassant-Sourdy S, Rochotte J, Cros J, Neuzillet C, Raffenne J, Duluc C, Perraud A, Nigri J, Gigoux V, Bieche I, Ponzo M, Carpentier G, Cascone I, Tomasini R, Schmid HA, Mathonnet M, Nicolle R, Bousquet MP, Martineau Y, Pyronnet S, Jean C, Bousquet C. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Cell Mol Gastroenterol Hepatol 2021;11:1405-36. [PMID: 33482394 DOI: 10.1016/j.jcmgh.2021.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Pedersen SF, Novak I, Alves F, Schwab A, Pardo LA. Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. BioEssays 2017;39:1600253. [DOI: 10.1002/bies.201600253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
106 Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27(27): 4298-4321 [PMID: 34366606 DOI: 10.3748/wjg.v27.i27.4298] [Reference Citation Analysis]
107 Brown ZJ, Martin SP, Carman R Jr. Integrating Osteopathic Philosophy in Cancer Care. J Am Osteopath Assoc 2019;119:391-4. [PMID: 31135867 DOI: 10.7556/jaoa.2019.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Moccia M, Caratelli V, Cinti S, Pede B, Avitabile C, Saviano M, Imbriani AL, Moscone D, Arduini F. Paper-based electrochemical peptide nucleic acid (PNA) biosensor for detection of miRNA-492: a pancreatic ductal adenocarcinoma biomarker. Biosens Bioelectron 2020;165:112371. [PMID: 32729503 DOI: 10.1016/j.bios.2020.112371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
109 Osterrieth JWM, Fairen-Jimenez D. Metal-Organic Framework Composites for Theragnostics and Drug Delivery Applications. Biotechnol J 2021;16:e2000005. [PMID: 32330358 DOI: 10.1002/biot.202000005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
110 Li Y, Zhao Z, Liu H, Fetse JP, Jain A, Lin CY, Cheng K. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Appl Mater Interfaces 2019;11:45390-403. [PMID: 31769963 DOI: 10.1021/acsami.9b15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
111 Bery N, Cruz-Migoni A, Bataille CJ, Quevedo CE, Tulmin H, Miller A, Russell A, Phillips SE, Carr SB, Rabbitts TH. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. Elife 2018;7:e37122. [PMID: 29989546 DOI: 10.7554/eLife.37122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
112 Xi Y, Jing Z, Haihong L, Yizhen J, Weili G, Shuwen H. Analysis of T lymphocyte-related biomarkers in pancreatic cancer. Pancreatology 2020;20:1502-10. [PMID: 32952042 DOI: 10.1016/j.pan.2020.09.005] [Reference Citation Analysis]
113 Li Z, Shao C, Liu X, Lu X, Jia X, Zheng X, Wang S, Zhu L, Li K, Pang Y, Xie F, Lu Y, Wang Y. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis 2020;41:44-55. [PMID: 31046123 DOI: 10.1093/carcin/bgz086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
114 Huang X, Zhang G. Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer. Front Cell Dev Biol 2020;8:602352. [PMID: 33282875 DOI: 10.3389/fcell.2020.602352] [Reference Citation Analysis]
115 Rasmussen LS, Fristrup CW, Jensen BV, Pfeiffer P, Weber B, Yilmaz MK, Poulsen LØ, Ladekarl M, Østerlind K, Larsen JS, Skuladottir H, Bøgsted M, Falkmer UG. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Pancreas 2021;50:685-95. [PMID: 34016900 DOI: 10.1097/MPA.0000000000001833] [Reference Citation Analysis]
116 Braun LM, Lagies S, Klar RFU, Hussung S, Fritsch RM, Kammerer B, Wittel UA. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Cancers (Basel) 2020;12:E1440. [PMID: 32492856 DOI: 10.3390/cancers12061440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
117 He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D, Zhang Q, Li L, Qin W, Jin H, Qian Q. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. Cell Immunol 2018;329:31-40. [PMID: 29859625 DOI: 10.1016/j.cellimm.2018.04.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
118 Driescher C, Fuchs K, Haeberle L, Goering W, Frohn L, Opitz FV, Haeussinger D, Knoefel WT, Keitel V, Esposito I. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers (Basel) 2020;13:E39. [PMID: 33375555 DOI: 10.3390/cancers13010039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Lozanovski VJ, Polychronidis G, Gross W, Gharabaghi N, Mehrabi A, Hackert T, Schemmer P, Herr I. Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study. Invest New Drugs 2020;38:776-84. [PMID: 31250356 DOI: 10.1007/s10637-019-00826-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
120 Sunami Y, Böker V, Kleeff J. Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers (Basel) 2021;13:697. [PMID: 33572223 DOI: 10.3390/cancers13040697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
121 Oyama H, Tada M, Takagi K, Tateishi K, Hamada T, Nakai Y, Hakuta R, Ijichi H, Ishigaki K, Kanai S, Kogure H, Mizuno S, Saito K, Saito T, Sato T, Suzuki T, Takahara N, Morishita Y, Arita J, Hasegawa K, Tanaka M, Fukayama M, Koike K. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.Gastroenterology. 2020;158:226-237.e5. [PMID: 31473224 DOI: 10.1053/j.gastro.2019.08.032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 17.7] [Reference Citation Analysis]
122 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Reference Citation Analysis]
123 Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786 [PMID: 32742988 DOI: 10.12998/wjcc.v8.i13.2778] [Reference Citation Analysis]
124 Gregório C, Soares-Lima SC, Alemar B, Recamonde-Mendoza M, Camuzi D, de Souza-Santos PT, Rivero R, Machado S, Osvaldt A, Ashton-Prolla P, Pinto LFR. Calcium Signaling Alterations Caused by Epigenetic Mechanisms in Pancreatic Cancer: From Early Markers to Prognostic Impact. Cancers (Basel) 2020;12:E1735. [PMID: 32629766 DOI: 10.3390/cancers12071735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
125 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
126 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
127 Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, Sánchez-Cabús S, Begthel H, Boj SF, Clevers H, Fillat C. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine 2020;56:102786. [PMID: 32460166 DOI: 10.1016/j.ebiom.2020.102786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
128 Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D. New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. Acta Pharm Sin B 2021;11:1148-57. [PMID: 34094825 DOI: 10.1016/j.apsb.2020.10.019] [Reference Citation Analysis]
129 Dhara S, Chhangawala S, Chintalapudi H, Askan G, Aveson V, Massa AL, Zhang L, Torres D, Makohon-Moore AP, Lecomte N, Melchor JP, Bermeo J, Cardenas A 3rd, Sinha S, Glassman D, Nicolle R, Moffitt R, Yu KH, Leppanen S, Laderman S, Curry B, Gui J, Balachandran VP, Iacobuzio-Donahue C, Chandwani R, Leslie CS, Leach SD. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nat Commun 2021;12:3044. [PMID: 34031415 DOI: 10.1038/s41467-021-23237-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Kokkinos J, Sharbeen G, Haghighi KS, Ignacio RMC, Kopecky C, Gonzales-Aloy E, Youkhana J, Timpson P, Pereira BA, Ritchie S, Pandzic E, Boyer C, Davis TP, Butler LM, Goldstein D, McCarroll JA, Phillips PA. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci Rep 2021;11:1944. [PMID: 33479301 DOI: 10.1038/s41598-021-81299-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
131 Wang S, Li M, Yan L, He M, Lin H, Xu Y, Wan Q, Qin G, Chen G, Xu M, Wang G, Qin Y, Luo Z, Tang X, Wang T, Zhao Z, Xu Y, Chen Y, Huo Y, Hu R, Ye Z, Dai M, Shi L, Gao Z, Su Q, Mu Y, Zhao J, Chen L, Zeng T, Yu X, Li Q, Shen F, Chen L, Zhang Y, Wang Y, Deng H, Liu C, Wu S, Yang T, Li D, Ning G, Wu T, Wang W, Bi Y, Lu J; 4C Study Group. Metabolomics study reveals systematic metabolic dysregulation and early detection markers associated with incident pancreatic cancer. Int J Cancer 2021. [PMID: 34792202 DOI: 10.1002/ijc.33877] [Reference Citation Analysis]
132 Li C, Peng Z, Wang Y, Lam G, Nissen N, Tang J, Yuan X, Lewis M, Greene MI, Pandol SJ, Wang Q. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Am J Physiol Gastrointest Liver Physiol 2021;320:G380-95. [PMID: 33501895 DOI: 10.1152/ajpgi.00185.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Morimoto D, Matsumura S, Bustos-Villalobos I, Sibal PA, Ichinose T, Naoe Y, Eissa IR, Abdelmoneim M, Mukoyama N, Miyajima N, Tanaka M, Kodera Y, Kasuya H. C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Cells 2021;10:1502. [PMID: 34203706 DOI: 10.3390/cells10061502] [Reference Citation Analysis]
134 Amrutkar M, Larsen EK, Aasrum M, Finstadsveen AV, Andresen PA, Verbeke CS, Gladhaug IP. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor. Cells 2020;9:E227. [PMID: 31963309 DOI: 10.3390/cells9010227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Wu C, Yang P, Liu B, Tang Y. Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma? Onco Targets Ther 2020;13:2551-62. [PMID: 32273725 DOI: 10.2147/OTT.S232464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Choi JI, Jang SI, Hong J, Kim CH, Kwon SS, Park JS, Lim JB. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. Cancer Lett 2021;498:42-53. [PMID: 33188841 DOI: 10.1016/j.canlet.2020.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
137 Xu MD, Liu SL, Feng YZ, Liu Q, Shen M, Zhi Q, Liu Z, Gu DM, Yu J, Shou LM, Gong FR, Zhu Q, Duan W, Chen K, Zhang J, Wu MY, Tao M, Li W. Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. Oncotarget 2017;8:14620-35. [PMID: 28099906 DOI: 10.18632/oncotarget.14678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
138 Reni M, Andreasi V, Gasparri AM, Dugnani E, Colombo B, Macchini M, Bianco M, Dallatomasina A, Citro A, Assi E, Protti MP, Esposito A, Falconi M, Curnis F, Piemonti L, Corti A. Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:613582. [PMID: 33425767 DOI: 10.3389/fonc.2020.613582] [Reference Citation Analysis]
139 Luo H, Galvão DA, Newton RU, Lopez P, Tang C, Fairman CM, Spry N, Taaffe DR. Exercise Medicine in the Management of Pancreatic Cancer: A Systematic Review. Pancreas 2021;50:280-92. [PMID: 33835957 DOI: 10.1097/MPA.0000000000001753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Védie A, Neuzillet C. Pancreatic cancer: Best supportive care. La Presse Médicale 2019;48:e175-85. [DOI: 10.1016/j.lpm.2019.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
141 Supadmanaba IGP, Mantini G, Randazzo O, Capula M, Muller IB, Cascioferro S, Diana P, Peters GJ, Giovannetti E. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Epigenetics 2021;:1-24. [PMID: 34057028 DOI: 10.1080/15592294.2021.1916697] [Reference Citation Analysis]
142 Mashayekhi V, Mocellin O, Fens MHAM, Krijger GC, Brosens LAA, Oliveira S. Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. Theranostics 2021;11:9022-37. [PMID: 34522225 DOI: 10.7150/thno.60350] [Reference Citation Analysis]
143 Perera CJ, Falasca M, Chari ST, Greenfield JR, Xu Z, Pirola RC, Wilson JS, Apte MV. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Cancers (Basel) 2021;13:5224. [PMID: 34680372 DOI: 10.3390/cancers13205224] [Reference Citation Analysis]
144 Xiang ZJ, Hu T, Wang Y, Wang H, Xu L, Cui N. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC). Biosci Rep 2020;40:BSR20201190. [PMID: 32510138 DOI: 10.1042/BSR20201190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
145 Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Med. 2020;9:1703-1711. [PMID: 31945808 DOI: 10.1002/cam4.2851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
146 Schmittgen TD, Sempere LF. Acinar Cell-Enriched-MicroRNA-802 Connects the Dots Between Kras Signaling, Acinar Ductal Metaplasia, and Pancreatic Cancer. Gastroenterology 2021:S0016-5085(21)03645-3. [PMID: 34662582 DOI: 10.1053/j.gastro.2021.10.011] [Reference Citation Analysis]
147 Liu M, Zhong J, Zeng Z, Huang K, Ye Z, Deng S, Chen H, Xu F, Li Q, Zhao G. Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Theranostics 2019;9:4795-810. [PMID: 31367258 DOI: 10.7150/thno.30988] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
148 Lee J, Kim D, Kim JH. Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway. Phytomedicine 2019;58:152762. [DOI: 10.1016/j.phymed.2018.11.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
149 Liu X, Gündel B, Li X, Liu J, Wright A, Löhr M, Arvidsson G, Heuchel R. 3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma. Transl Oncol 2021;14:101107. [PMID: 33946033 DOI: 10.1016/j.tranon.2021.101107] [Reference Citation Analysis]
150 Phillips AE, Shah N, Borhani AA, Yadav D, Brand RE. Prior History of Pancreatitis Accelerates the Development of Pancreatic Adenocarcinoma. Pancreas. 2018;47:1262-1266. [PMID: 30286010 DOI: 10.1097/mpa.0000000000001160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
151 Park JK, Hank T, Scherber CM, Lillemoe KD, Fernández-Del Castillo C, Warshaw AL, Toner M, Irimia D, Thayer SP, Liss AS. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Pancreas 2020;49:128-34. [PMID: 31856088 DOI: 10.1097/MPA.0000000000001459] [Reference Citation Analysis]
152 Silke J, O'Reilly LA. NF-κB and Pancreatic Cancer; Chapter and Verse. Cancers (Basel) 2021;13:4510. [PMID: 34572737 DOI: 10.3390/cancers13184510] [Reference Citation Analysis]
153 Kleeff J, Michl P. Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncol. 2017;18:421-422. [PMID: 28259609 DOI: 10.1016/s1470-2045(17)30087-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
154 Hoque N, Hasan CM, Rana MS, Varsha A, Sohrab MH, Rahman KM. Fusaproliferin, a Fungal Mycotoxin, Shows Cytotoxicity against Pancreatic Cancer Cell Lines. Molecules 2018;23:E3288. [PMID: 30545017 DOI: 10.3390/molecules23123288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
155 Dai E, Han L, Liu J, Xie Y, Zeh HJ, Kang R, Bai L, Tang D. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun 2020;11:6339. [PMID: 33311482 DOI: 10.1038/s41467-020-20154-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 10.5] [Reference Citation Analysis]
156 Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
157 An X, Liu L, Schaefer M, Yan B, Scholz C, Hillmer S, Wang K, Luo Y, Ji H, Gladkich J, Herr I. Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer. Cancers (Basel) 2021;13:4770. [PMID: 34638256 DOI: 10.3390/cancers13194770] [Reference Citation Analysis]
158 Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, K Pandey M, C Pramanik K. Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance. Int J Mol Sci 2019;20:E4242. [PMID: 31480221 DOI: 10.3390/ijms20174242] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
159 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
160 Pan J, Ge X, Zhou W, Zhong X, Gu L, Zhu H, Li X, Qi W, Wang X. Comparison of clinical outcomes between mesh-reinforced pancreatojejunostomy and pancreatogastrostomy following pancreaticoduodenectomy: a cohort study. World J Surg Oncol 2018;16:190. [PMID: 30223846 DOI: 10.1186/s12957-018-1491-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
161 Luo D, Digiovanni MG, Wei R, Lacomb JF, Williams JL, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis 2020;41:927-39. [PMID: 31584613 DOI: 10.1093/carcin/bgz170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2017;31:43-51. [PMID: 28867243 DOI: 10.1016/j.drup.2017.07.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
163 El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol 2019;15:437-47. [PMID: 31100206 DOI: 10.1080/17425255.2019.1620731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
164 Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ting Y, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Lerch MM, Mayerle J, Tjaden C, Strobel O, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg 2019;154:1038-48. [PMID: 31483448 DOI: 10.1001/jamasurg.2019.3337] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 22.5] [Reference Citation Analysis]
165 Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR, Timpson P. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Trends in Cancer 2019;5:724-41. [DOI: 10.1016/j.trecan.2019.09.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 24.0] [Reference Citation Analysis]
166 Krishnamoorthy M, Lenehan JG, Burton JP, Maleki Vareki S. Immunomodulation in Pancreatic Cancer. Cancers (Basel) 2020;12:E3340. [PMID: 33198059 DOI: 10.3390/cancers12113340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
167 Lee HK, Yoon YS, Han HS, Lee JS, Na HY, Ahn S, Park J, Jung K, Jung JH, Kim J, Hwang JH, Lee JC. Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4454. [PMID: 34503264 DOI: 10.3390/cancers13174454] [Reference Citation Analysis]
168 Zhang X, Liu Y, Zhang Z, Tan J, Zhang J, Ou H, Li J, Song Z. Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature. Front Cell Dev Biol 2021;9:649265. [PMID: 33748143 DOI: 10.3389/fcell.2021.649265] [Reference Citation Analysis]
169 Yu J, Li Q, Zhang H, Meng Y, Liu YF, Jiang H, Ma C, Liu F, Fang X, Li J, Feng X, Shao C, Bian Y, Lu J. Contrast-enhanced computed tomography radiomics and multilayer perceptron network classifier: an approach for predicting CD20+ B cells in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2021. [PMID: 34708252 DOI: 10.1007/s00261-021-03285-4] [Reference Citation Analysis]
170 Tabang DN, Ford M, Li L. Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases. Front Chem 2021;9:707387. [PMID: 34368082 DOI: 10.3389/fchem.2021.707387] [Reference Citation Analysis]
171 Gajate C, Gayet O, Fraunhoffer NA, Iovanna J, Dusetti N, Mollinedo F. Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition. Cancers (Basel) 2021;13:6124. [PMID: 34885233 DOI: 10.3390/cancers13236124] [Reference Citation Analysis]
172 Liu Y, Bi T, Liu L, Gao Q, Shen G, Qin L. RETRACTED ARTICLE: S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn-Schmiedeberg's Arch Pharmacol 2019;392:615-22. [DOI: 10.1007/s00210-019-01617-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
173 Korc M, Jeon CY, Edderkaoui M, Pandol SJ, Petrov MS;  Consortium for the Study of Chronic Pancreatitis; Diabetes, and Pancreatic Cancer (CPDPC). Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31:529-536. [PMID: 29195672 DOI: 10.1016/j.bpg.2017.09.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
174 Xu Y, Wang Y, Höti N, Clark DJ, Chen SY, Zhang H. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrom Rev 2021;:e21748. [PMID: 34766650 DOI: 10.1002/mas.21748] [Reference Citation Analysis]
175 Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, Hong TH, Choi MG. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9:326-334. [PMID: 29399990 DOI: 10.1002/jcsm.12274] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
176 Gao F, Liu G, Wang J, Huang S, Ding F, Lian W, Lv X, Guo Y, Fan X, Zhang S, Liu Q. Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma. Oxid Med Cell Longev 2021;2021:2088345. [PMID: 34394823 DOI: 10.1155/2021/2088345] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life (Basel) 2021;11:843. [PMID: 34440587 DOI: 10.3390/life11080843] [Reference Citation Analysis]
179 Kim M, Hwang DG, Jang J. 3D Pancreatic Tissue Modeling in vitro: Advances and Prospects. BioChip J 2020;14:84-99. [DOI: 10.1007/s13206-020-4108-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
180 Grinshpun A, Zarbiv Y, Roszik J, Subbiah V, Hubert A. Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Case Rep Oncol 2019;12:7-13. [PMID: 30792639 DOI: 10.1159/000496018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
181 Geyer M, Queiroz K. Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening. Front Cell Dev Biol 2021;9:761807. [PMID: 35004672 DOI: 10.3389/fcell.2021.761807] [Reference Citation Analysis]
182 Kirkegård J, Lund JL, Mortensen FV, Cronin-Fenton D. Statins and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study. Int J Cancer 2020;146:610-6. [PMID: 30861115 DOI: 10.1002/ijc.32264] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
183 Randazzo O, Papini F, Mantini G, Gregori A, Parrino B, Liu DSK, Cascioferro S, Carbone D, Peters GJ, Frampton AE, Garajova I, Giovannetti E. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2020;12:E3206. [PMID: 33142664 DOI: 10.3390/cancers12113206] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
184 Juarez-Flores A, José MV. Multivariate Entropy Characterizes the Gene Expression and Protein-Protein Networks in Four Types of Cancer. Entropy (Basel) 2018;20:E154. [PMID: 33265245 DOI: 10.3390/e20030154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Nagireddy PKR, Kommalapati VK, Siva Krishna V, Sriram D, Tangutur AD, Kantevari S. Imidazo[2,1-b]thiazole-Coupled Natural Noscapine Derivatives as Anticancer Agents. ACS Omega 2019;4:19382-98. [PMID: 31763563 DOI: 10.1021/acsomega.9b02789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
186 Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, Hua J, Yu X, Shi S. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Mol Cancer 2019;18:184. [PMID: 31831007 DOI: 10.1186/s12943-019-1117-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
187 Kim SK, Jang SD, Kim H, Chung S, Park JK, Kuh HJ. Phenotypic Heterogeneity and Plasticity of Cancer Cell Migration in a Pancreatic Tumor Three-Dimensional Culture Model. Cancers (Basel) 2020;12:E1305. [PMID: 32455681 DOI: 10.3390/cancers12051305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
188 Gao F, Griffin N, Faulkner S, Li X, King SJ, Jobling P, Denham JW, Jiang CC, Hondermarck H. The Membrane Protein Sortilin Can Be Targeted to Inhibit Pancreatic Cancer Cell Invasion. Am J Pathol 2020;190:1931-42. [PMID: 32526166 DOI: 10.1016/j.ajpath.2020.05.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
189 Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, Liu LM. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Life Sci 2021;:119205. [PMID: 33571515 DOI: 10.1016/j.lfs.2021.119205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
190 Pothula SP, Xu Z, Goldstein D, Merrett N, Pirola RC, Wilson JS, Apte MV. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Oncotarget 2017;8:76722-39. [PMID: 29100344 DOI: 10.18632/oncotarget.20822] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
191 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
192 Gits HC, Tang AH, Harmsen WS, Bamlet WR, Graham RP, Petersen GM, Smyrk TC, Mahipal A, Kowalchuk RO, Ashman JB, Rule WG, Owen D, Neben Wittich MA, McWilliams RR, Halfdanarson T, Ma WW, Sio TT, Cleary SP, Truty MJ, Haddock MG, Hallemeier CL, Merrell KW. Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. J Gastrointest Oncol 2021;12:2275-86. [PMID: 34790392 DOI: 10.21037/jgo-21-55] [Reference Citation Analysis]
193 Li J, Chen X, Kang R, Zeh H, Klionsky DJ, Tang D. Regulation and function of autophagy in pancreatic cancer. Autophagy. [DOI: 10.1080/15548627.2020.1847462] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
194 Görte J, Beyreuther E, Danen EHJ, Cordes N. Comparative Proton and Photon Irradiation Combined with Pharmacological Inhibitors in 3D Pancreatic Cancer Cultures. Cancers (Basel) 2020;12:E3216. [PMID: 33142778 DOI: 10.3390/cancers12113216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
195 Lee J, Lee J, Choi C, Kim JH. Blockade of integrin α3 attenuates human pancreatic cancer via inhibition of EGFR signalling. Sci Rep 2019;9:2793. [PMID: 30808960 DOI: 10.1038/s41598-019-39628-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
196 Principe DR, Timbers KE, Atia LG, Koch RM, Rana A. TGFβ Signaling in the Pancreatic Tumor Microenvironment. Cancers (Basel) 2021;13:5086. [PMID: 34680235 DOI: 10.3390/cancers13205086] [Reference Citation Analysis]
197 Karpiński TM. The Microbiota and Pancreatic Cancer. Gastroenterol Clin North Am 2019;48:447-64. [PMID: 31383281 DOI: 10.1016/j.gtc.2019.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
198 Jurcak N, Zheng L. Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve. Pharmacol Ther. 2019;pii:S0163-7258(19)30073-7. [PMID: 31047906 DOI: 10.1016/j.pharmthera.2019.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
199 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
200 Albahde MAH, Abdrakhimov B, Li GQ, Zhou X, Zhou D, Xu H, Qian H, Wang W. The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. Front Oncol 2021;11:640863. [PMID: 34094924 DOI: 10.3389/fonc.2021.640863] [Reference Citation Analysis]
201 Taniai T, Haruki K, Matsumoto M, Sakamoto T, Shiba H, Yanaga K. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. Int Cancer Conf J 2019;8:190-4. [PMID: 31559121 DOI: 10.1007/s13691-019-00382-6] [Reference Citation Analysis]
202 Wang Y, Li H, Li F. ELMO2 association with Gαi2 regulates pancreatic cancer cell chemotaxis and metastasis. PeerJ 2020;8:e8910. [PMID: 32292657 DOI: 10.7717/peerj.8910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Cortez NE, Mackenzie GG. Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular Mechanisms and Clinical Perspectives. Nutrients 2021;13:3202. [PMID: 34579079 DOI: 10.3390/nu13093202] [Reference Citation Analysis]
204 Wang F, Xia X, Yang C, Shen J, Mai J, Kim HC, Kirui D, Kang Y, Fleming JB, Koay EJ, Mitra S, Ferrari M, Shen H. SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 2018;24:3176-85. [PMID: 29602802 DOI: 10.1158/1078-0432.CCR-17-3435] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
205 Karunakaran M, Barreto SG. Surgery for pancreatic cancer: current controversies and challenges. Future Oncol 2021. [PMID: 34747183 DOI: 10.2217/fon-2021-0533] [Reference Citation Analysis]
206 Jones RP, Ghaneh P, Neoptolemos JP. Adjuvant Chemotherapy in Pancreatic Cancer. In: Beger HG, Warshaw AL, Hruban RH, Büchler MW, Lerch MM, Neoptolemos JP, Shimosegawa T, Whitcomb DC, Groß C, editors. The Pancreas. Chichester: John Wiley & Sons, Ltd; 2018. pp. 847-55. [DOI: 10.1002/9781119188421.ch113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Müller D, Shin S, Goullet de Rugy T, Samain R, Baer R, Strehaiano M, Masvidal-Sanz L, Guillermet-Guibert J, Jean C, Tsukumo Y, Sonenberg N, Marion F, Guilbaud N, Hoffmann JS, Larsson O, Bousquet C, Pyronnet S, Martineau Y. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight 2019;4:121951. [PMID: 31672935 DOI: 10.1172/jci.insight.121951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
208 Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9. [PMID: 29144412 DOI: 10.3390/cancers9110157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 28.4] [Reference Citation Analysis]
209 Yang S, Zhang H, Ren X. The application of high-field magnetic resonance perfusion imaging in the diagnosis of pancreatic cancer. Medicine (Baltimore) 2017;96:e7571. [PMID: 28885324 DOI: 10.1097/MD.0000000000007571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Wang W, Park C, Oh E, Sung Y, Lee J, Park K, Kang H. Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta , Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway. J Nat Prod 2019;82:3357-65. [DOI: 10.1021/acs.jnatprod.9b00646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
211 Kamyabi N, Bernard V, Maitra A. Liquid biopsies in pancreatic cancer. Expert Rev Anticancer Ther 2019;19:869-78. [PMID: 31533487 DOI: 10.1080/14737140.2019.1670063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
212 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
213 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Palamaris K, Felekouras E, Sakellariou S. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers (Basel) 2021;13:5532. [PMID: 34771695 DOI: 10.3390/cancers13215532] [Reference Citation Analysis]
215 Tabibzadeh A, Tameshkel FS, Moradi Y, Soltani S, Moradi-Lakeh M, Ashrafi GH, Motamed N, Zamani F, Motevalian SA, Panahi M, Esghaei M, Ajdarkosh H, Mousavi-Jarrahi A, Niya MHK. Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis. Sci Rep 2020;10:18713. [PMID: 33127962 DOI: 10.1038/s41598-020-73770-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
216 Ou A, Schmidberger JW, Wilson KA, Evans CW, Hargreaves JA, Grigg M, O'Mara ML, Iyer KS, Bond CS, Smith NM. High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A π-stacking interactions for small-molecule recognition. Nucleic Acids Res 2020;48:5766-76. [PMID: 32313953 DOI: 10.1093/nar/gkaa262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
217 Xu JL, Guo Y. A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target. Invest New Drugs 2021. [PMID: 34515878 DOI: 10.1007/s10637-021-01176-5] [Reference Citation Analysis]
218 Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017;28:1117-1123. [PMID: 28327906 DOI: 10.1093/annonc/mdx033] [Cited by in Crossref: 128] [Cited by in F6Publishing: 127] [Article Influence: 32.0] [Reference Citation Analysis]
219 Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E4067. [PMID: 32517181 DOI: 10.3390/ijms21114067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
220 Frappart PO, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers (Basel) 2020;12:E2750. [PMID: 32987786 DOI: 10.3390/cancers12102750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
221 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Liu X, Zhou L, Chen Y, Jiang X, Jiang J. CircRNF13 Promotes the Malignant Progression of Pancreatic Cancer through Targeting miR-139-5p/IGF1R Axis. J Oncol 2021;2021:6945046. [PMID: 34899908 DOI: 10.1155/2021/6945046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Xie D, Qian B, Yang J, Peng X, Li Y, Hu T, Lu S, Chen X, Han Y. Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis. Front Oncol 2020;10:598048. [PMID: 33194764 DOI: 10.3389/fonc.2020.598048] [Reference Citation Analysis]
224 Zhu D, Huang H, Pinkas DM, Luo J, Ganguly D, Fox AE, Arner E, Xiang Q, Tu ZC, Bullock AN, Brekken RA, Ding K, Lu X. 2-Amino-2,3-dihydro-1H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. J Med Chem 2019;62:7431-44. [PMID: 31310125 DOI: 10.1021/acs.jmedchem.9b00365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
225 Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Int J Mol Sci 2021;22:10944. [PMID: 34681603 DOI: 10.3390/ijms222010944] [Reference Citation Analysis]
226 Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci 2017;18:E779. [PMID: 28383487 DOI: 10.3390/ijms18040779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
227 Georgikou C, Yin L, Gladkich J, Xiao X, Sticht C, Torre CDL, Gretz N, Gross W, Schäfer M, Karakhanova S, Herr I. Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer. Cancer Letters 2020;469:238-45. [DOI: 10.1016/j.canlet.2019.10.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
228 Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
229 Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, Mcdonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet 2017;389:1011-24. [DOI: 10.1016/s0140-6736(16)32409-6] [Cited by in Crossref: 832] [Cited by in F6Publishing: 379] [Article Influence: 166.4] [Reference Citation Analysis]
230 Uchino Y, Muroya D, Yoshitomi M, Shichijo S, Yamada A, Sasada T, Yamada T, Okuda K, Itoh K, Yutani S. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer. Mol Clin Oncol 2021;14:39. [PMID: 33437477 DOI: 10.3892/mco.2020.2201] [Reference Citation Analysis]
231 Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, Hippisley-Cox J. Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine neoplasms: a nested case-control study of the UK primary care population. Br J Gen Pract 2021;71:e836-45. [PMID: 34544691 DOI: 10.3399/BJGP.2021.0153] [Reference Citation Analysis]
232 Gustavell T, Langius-Eklöf A, Wengström Y, Segersvärd R, Sundberg K. Development and Feasibility of an Interactive Smartphone App for Early Assessment and Management of Symptoms Following Pancreaticoduodenectomy. Cancer Nurs 2019;42:E1-E10. [PMID: 29596113 DOI: 10.1097/NCC.0000000000000584] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
233 Maruyama T, Sasaki A, Iijima S, Ayukawa S, Goda N, Tazuru K, Hashimoto N, Hayashi T, Kozawa K, Sato N, Ishikawa S, Morita T, Fujita Y. ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition. iScience 2020;23:101327. [PMID: 32688284 DOI: 10.1016/j.isci.2020.101327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
234 Lewis HL, Chakedis JM, Talbert E, Haverick E, Rajasekera P, Hart P, Bloomston M, Dillhoff M, Pawlik TM, Guttridge D, Schmidt CR. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. J Surg Oncol 2018;117:1260-6. [DOI: 10.1002/jso.24940] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
235 Deng Y, Tu H, Pierzynski JA, Miller ED, Gu X, Huang M, Chang DW, Ye Y, Hildebrandt MAT, Klein AP, Zhao R, Lippman SM, Wu X. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 2018;92:20-32. [PMID: 29413686 DOI: 10.1016/j.ejca.2017.12.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
236 Wang H, Yu S, Peng H, Shu Y, Zhang W, Zhu Q, Wu Y, Xu Y, Yan J, Xiang H. Long noncoding RNA Linc00337 functions as an E2F1 co-activator and promotes cell proliferation in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2020;39:216. [PMID: 33054826 DOI: 10.1186/s13046-020-01725-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
237 Nichetti F, Marra A, Corti F, Guidi A, Raimondi A, Prinzi N, de Braud F, Pusceddu S. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. Target Oncol 2018;13:333-51. [PMID: 29656320 DOI: 10.1007/s11523-018-0567-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
238 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
239 Villarino N, Signaevskaia L, van Niekerk J, Medal R, Kim H, Lahmy R, Scully K, Pinkerton A, Kim S, Lowy A, Itkin-Ansari P. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 2017;8:53154-67. [PMID: 28881801 DOI: 10.18632/oncotarget.18587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
240 Urrutia G, Salmonson A, Toro-Zapata J, de Assuncao TM, Mathison A, Dusetti N, Iovanna J, Urrutia R, Lomberk G. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. Mol Cancer Res 2020;18:448-62. [PMID: 31822519 DOI: 10.1158/1541-7786.MCR-19-0490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
241 Barbour AP, Samra JS, Haghighi KS, Donoghoe MW, Burge M, Harris MT, Chua YJ, Mitchell J, O'Rourke N, Chan H, Gebski VJ, Gananadha S, Croagh DG, Kench JG, Goldstein D; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Ann Surg Oncol 2020;27:2506-15. [PMID: 31997125 DOI: 10.1245/s10434-020-08205-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
242 Jonckheere N, Vincent A, Neve B, Van Seuningen I. Mucin expression, epigenetic regulation and patient survival: A toolkit of prognostic biomarkers in epithelial cancers. Biochim Biophys Acta Rev Cancer 2021;1876:188538. [PMID: 33862149 DOI: 10.1016/j.bbcan.2021.188538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Abdel Mouti M, Pauklin S. TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. Mol Ther 2021;29:920-36. [PMID: 33429081 DOI: 10.1016/j.ymthe.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
244 Koikawa K, Ohuchida K, Ando Y, Kibe S, Nakayama H, Takesue S, Endo S, Abe T, Okumura T, Iwamoto C, Moriyama T, Nakata K, Miyasaka Y, Ohtsuka T, Nagai E, Mizumoto K, Hashizume M, Nakamura M. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Cancer Letters 2018;425:65-77. [DOI: 10.1016/j.canlet.2018.03.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
245 Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ, Chen Z. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem Biophys Res Commun 2018;500:691-7. [PMID: 29678579 DOI: 10.1016/j.bbrc.2018.04.137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
246 Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut 2019;68:159-71. [PMID: 30177543 DOI: 10.1136/gutjnl-2018-316451] [Cited by in Crossref: 104] [Cited by in F6Publishing: 107] [Article Influence: 26.0] [Reference Citation Analysis]
247 Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Gastroenterology 2018;154:820-38. [PMID: 29287624 DOI: 10.1053/j.gastro.2017.11.280] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 19.6] [Reference Citation Analysis]
248 Lee JJ, Bernard V, Semaan A, Monberg ME, Huang J, Stephens BM, Lin D, Rajapakshe KI, Weston BR, Bhutani MS, Haymaker CL, Bernatchez C, Taniguchi CM, Maitra A, Guerrero PA. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Clin Cancer Res 2021;27:5912-21. [PMID: 34426439 DOI: 10.1158/1078-0432.CCR-20-3925] [Reference Citation Analysis]
249 Xu X, Qian D, Liu H, Cruz D, Luo S, Walsh KM, Abbruzzese JL, Zhang X, Wei Q. Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. Mol Carcinog 2019;58:1338-48. [PMID: 30997723 DOI: 10.1002/mc.23018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
250 Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969-2974. [PMID: 32209560 DOI: 10.1158/0008-5472.can-19-3682] [Cited by in Crossref: 87] [Cited by in F6Publishing: 64] [Article Influence: 43.5] [Reference Citation Analysis]
251 Liu X, Li Z, Wang Y. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Adv Biol (Weinh) 2021;5:e1900236. [PMID: 33729700 DOI: 10.1002/adbi.201900236] [Reference Citation Analysis]
252 Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. KRAS-related proteins in pancreatic cancer. Pharmacol Ther 2016;168:29-42. [PMID: 27595930 DOI: 10.1016/j.pharmthera.2016.09.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
253 Jugniot N, Bam R, Meuillet EJ, Unger EC, Paulmurugan R. Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer. Bioeng Transl Med 2021;6:e10183. [PMID: 33532585 DOI: 10.1002/btm2.10183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
254 Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. J Clin Med. 2020;9. [PMID: 32121198 DOI: 10.3390/jcm9030648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
255 Johnston A, Serhal A, Lopes Vendrami C, McCarthy RJ, Komanduri S, Horowitz JM, Nikolaidis P, Miller FH. The abrupt pancreatic duct cutoff sign on MDCT and MRI. Abdom Radiol (NY) 2020;45:2476-84. [PMID: 32444890 DOI: 10.1007/s00261-020-02582-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
256 Liberelle M, Magnez R, Thuru X, Bencheikh Y, Ravez S, Quenon C, Drucbert AS, Foulon C, Melnyk P, Van Seuningen I, Lebègue N. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis. Sci Rep 2019;9:16678. [PMID: 31723153 DOI: 10.1038/s41598-019-53099-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
257 Zhang Y, Ye M, Huang F, Wang S, Wang H, Mou X, Wang Y. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma. Hum Gene Ther 2020;31:891-903. [PMID: 32475172 DOI: 10.1089/hum.2020.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
258 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
259 Berger NA. Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map? Transl Cancer Res 2016;5:S243-7. [PMID: 27656419 DOI: 10.21037/tcr.2016.08.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Huang X, Pan L, Zuo Z, Li M, Zeng L, Li R, Ye Y, Zhang J, Wu G, Bai R, Zhuang L, Wei L, Zheng Y, Su J, Deng J, Deng S, Zhang S, Zhu S, Che X, Wang C, Wu C, Chen R, Lin D, Zheng J. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Nat Commun 2021;12:3830. [PMID: 34158490 DOI: 10.1038/s41467-021-23904-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther 2017;24:100-5. [PMID: 27910857 DOI: 10.1038/cgt.2016.65] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
262 Gustavell T, Sundberg K, Segersvärd R, Wengström Y, Langius-eklöf A. Decreased symptom burden following surgery due to support from an interactive app for symptom management for patients with pancreatic and periampullary cancer. Acta Oncologica 2019;58:1307-14. [DOI: 10.1080/0284186x.2019.1633473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
263 Matsuzawa F, Kamachi H, Mizukami T, Einama T, Kawamata F, Fujii Y, Fukai M, Kobayashi N, Hatanaka Y, Taketomi A. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells. BMC Cancer 2021;21:200. [PMID: 33637083 DOI: 10.1186/s12885-020-07722-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Liu HY, Korc M, Lin CC. Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. Biomaterials 2018;160:24-36. [PMID: 29353105 DOI: 10.1016/j.biomaterials.2018.01.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
265 Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. JCI Insight 2021;6:141532. [PMID: 33764904 DOI: 10.1172/jci.insight.141532] [Reference Citation Analysis]
266 Wakiya T, Ishido K, Kimura N, Nagase H, Kubota S, Fujita H, Hagiwara Y, Kanda T, Matsuzaka M, Sasaki Y, Hakamada K. Prediction of massive bleeding in pancreatic surgery based on preoperative patient characteristics using a decision tree. PLoS One 2021;16:e0259682. [PMID: 34752505 DOI: 10.1371/journal.pone.0259682] [Reference Citation Analysis]
267 Ma L, Zhai B, Zhu H, Li W, Jiang W, Lei L, Zhang S, Qiao H, Jiang X, Sun X. The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer. Cancer Cell Int 2019;19:248. [PMID: 31572065 DOI: 10.1186/s12935-019-0963-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
268 Makohon-Moore AP, Matsukuma K, Zhang M, Reiter JG, Gerold JM, Jiao Y, Sikkema L, Attiyeh MA, Yachida S, Sandone C, Hruban RH, Klimstra DS, Papadopoulos N, Nowak MA, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 2018;561:201-5. [PMID: 30177826 DOI: 10.1038/s41586-018-0481-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
269 Chao MW, Chang LH, Tu HJ, Chang CD, Lai MJ, Chen YY, Liou JP, Teng CM, Pan SL. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clin Epigenetics 2019;11:85. [PMID: 31142371 DOI: 10.1186/s13148-019-0681-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
270 Lenggenhager D, Amrutkar M, Sántha P, Aasrum M, Löhr JM, Gladhaug IP, Verbeke CS. Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. Cells 2019;8:E23. [PMID: 30621293 DOI: 10.3390/cells8010023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
271 Hossan MS, Break MKB, Bradshaw TD, Collins HM, Wiart C, Khoo TJ, Alafnan A. Novel Semi-Synthetic Cu (II)-Cardamonin Complex Exerts Potent Anticancer Activity against Triple-Negative Breast and Pancreatic Cancer Cells via Inhibition of the Akt Signaling Pathway. Molecules 2021;26:2166. [PMID: 33918814 DOI: 10.3390/molecules26082166] [Reference Citation Analysis]
272 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. Br J Cancer 2018;118:1084-8. [PMID: 29523831 DOI: 10.1038/s41416-018-0005-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
273 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
274 Pramanik KC, Makena MR, Bhowmick K, Pandey MK. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer. Int J Mol Sci 2018;19:E3890. [PMID: 30563089 DOI: 10.3390/ijms19123890] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
275 de Oliveira G, Freire PP, Cury SS, de Moraes D, Oliveira JS, Dal-Pai-Silva M, Reis PP, Carvalho RF. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020;12:716. [PMID: 32197468 DOI: 10.3390/cancers12030716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
276 Carioli G, Bertuccio P, Malvezzi M, Rodriguez T, Levi F, Boffetta P, La Vecchia C, Negri E. Cancer mortality predictions for 2019 in Latin America. Int J Cancer 2020;147:619-32. [PMID: 31637709 DOI: 10.1002/ijc.32749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
277 Gopalan V, Singh A, Rashidi Mehrabadi F, Wang L, Ruppin E, Arda HE, Hannenhalli S. A Transcriptionally Distinct Subpopulation of Healthy Acinar Cells Exhibit Features of Pancreatic Progenitors and PDAC. Cancer Res 2021;81:3958-70. [PMID: 34049974 DOI: 10.1158/0008-5472.CAN-21-0427] [Reference Citation Analysis]
278 Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res 2021;40:382. [PMID: 34857016 DOI: 10.1186/s13046-021-02153-9] [Reference Citation Analysis]
279 Dardare J, Witz A, Merlin JL, Gilson P, Harlé A. SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E3534. [PMID: 32429474 DOI: 10.3390/ijms21103534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
280 Pfeifer T, Bai L, Gladkich J, Gross W, Liu L, Herr I, Schaefer M. Therapy of pancreatic cancer with alternating electric fields: Limitations of the method. Bioelectrochemistry 2021;141:107881. [PMID: 34245959 DOI: 10.1016/j.bioelechem.2021.107881] [Reference Citation Analysis]
281 Zhao X, Li H, Lyu S, Zhai J, Ji Z, Zhang Z, Zhang X, Liu Z, Wang H, Xu J, Fan H, Kou J, Li L, Lang R, He Q. Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma. Int J Biol Sci 2021;17:2590-605. [PMID: 34326696 DOI: 10.7150/ijbs.58886] [Reference Citation Analysis]
282 Emmanouilidi A, Fyffe CA, Ferro R, Edling CE, Capone E, Sestito S, Rapposelli S, Lattanzio R, Iacobelli S, Sala G, Maffucci T, Falasca M. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. J Exp Clin Cancer Res 2019;38:191. [PMID: 31088502 DOI: 10.1186/s13046-019-1191-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
283 Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci 2019;20:E4504. [PMID: 31514451 DOI: 10.3390/ijms20184504] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 21.3] [Reference Citation Analysis]
284 Hermann PC, Sainz B Jr. Pancreatic cancer stem cells: A state or an entity? Semin Cancer Biol 2018;53:223-31. [PMID: 30130664 DOI: 10.1016/j.semcancer.2018.08.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
285 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
286 Raufi AG, Breakstone R, Leonard K, Charpentier K, Beard R, Renaud J, Cavanaugh L, Sturtevant A, MacKinnon K, Almhanna K, Olszewski A, Safran HP. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295).Am J Clin Oncol. 2020;43:857-860. [PMID: 32976178 DOI: 10.1097/COC.0000000000000762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
287 Habib JR, Wolfgang CL. Commentary: Anatomic versus biologic resectability: The role of predictive biomarkers in guiding surgical management. Surgery 2020;168:1017-8. [PMID: 32900493 DOI: 10.1016/j.surg.2020.07.032] [Reference Citation Analysis]
288 Sunami Y, Häußler J, Kleeff J. Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers (Basel) 2020;12:E3770. [PMID: 33333727 DOI: 10.3390/cancers12123770] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
289 Robinson CM, Talty A, Logue SE, Mnich K, Gorman AM, Samali A. An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer. Cancers (Basel) 2021;13:E261. [PMID: 33445669 DOI: 10.3390/cancers13020261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
290 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
291 Huang W, Xue L, Xu H, Kong Z, Xu J, Zhao H, Nie Y. Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta-analysis. Int J Clin Pract 2021;75:e14443. [PMID: 34105851 DOI: 10.1111/ijcp.14443] [Reference Citation Analysis]
292 Arpalahti L, Haglund C, Holmberg CI. Proteostasis Dysregulation in Pancreatic Cancer. Adv Exp Med Biol 2020;1233:101-15. [PMID: 32274754 DOI: 10.1007/978-3-030-38266-7_4] [Reference Citation Analysis]
293 Jain T, Dudeja V. The war against pancreatic cancer in 2020 - advances on all fronts. Nat Rev Gastroenterol Hepatol 2021;18:99-100. [PMID: 33414515 DOI: 10.1038/s41575-020-00410-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
294 Chen Y, Xu R, Ruze R, Yang J, Wang H, Song J, You L, Wang C, Zhao Y. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Cancer Cell Int 2021;21:291. [PMID: 34090418 DOI: 10.1186/s12935-021-01928-6] [Reference Citation Analysis]
295 Corradi C, Gentiluomo M, Gajdán L, Cavestro GM, Kreivenaite E, Di Franco G, Sperti C, Giaccherini M, Petrone MC, Tavano F, Gioffreda D, Morelli L, Soucek P, Andriulli A, Izbicki JR, Napoli N, Małecka-Panas E, Hegyi P, Neoptolemos JP, Landi S, Vashist Y, Pasquali C, Lu Y, Cervena K, Theodoropoulos GE, Moz S, Capurso G, Strobel O, Carrara S, Hackert T, Hlavac V, Archibugi L, Oliverius M, Vanella G, Vodicka P, Arcidiacono PG, Pezzilli R, Milanetto AC, Lawlor RT, Ivanauskas A, Szentesi A, Kupcinskas J, Testoni SGG, Lovecek M, Nentwich M, Gazouli M, Luchini C, Zuppardo RA, Darvasi E, Brenner H, Gheorghe C, Jamroziak K, Canzian F, Campa D. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Int J Cancer 2021;148:2779-88. [PMID: 33534179 DOI: 10.1002/ijc.33475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
296 Glaß M, Dorn A, Hüttelmaier S, Haemmerle M, Gutschner T. Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Cancers (Basel) 2020;12:E2077. [PMID: 32727085 DOI: 10.3390/cancers12082077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Jiang J, Liu R, Zhang Z, Zhang X, Qi R, Chen S, Zhang X, Xi Y, Guo Q, Zheng H, Hua B. Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine: A study protocol of a multicenter prospective cohort study. Medicine (Baltimore) 2019;98:e17975. [PMID: 31764804 DOI: 10.1097/MD.0000000000017975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Wu LM, Zhang LL, Chen XH, Zheng SS. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers? Hepatobiliary Pancreat Dis Int. 2019;18:117-124. [PMID: 30655073 DOI: 10.1016/j.hbpd.2019.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
299 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
300 Lotfi Z, Najjary S, Lotfi F, Amini M, Baghbanzadeh A, Rashid DJ, Asl ER, Baradaran B, Mokhtarzadeh A. Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma. Eur J Pharmacol 2021;901:174006. [PMID: 33711308 DOI: 10.1016/j.ejphar.2021.174006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Milan M, Diaferia GR, Natoli G. Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants. EMBO J 2021;40:e107206. [PMID: 33844319 DOI: 10.15252/embj.2020107206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Wang L, Liu X, Zhou Q, Sui M, Lu Z, Zhou Z, Tang J, Miao Y, Zheng M, Wang W, Shen Y. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials 2017;144:105-18. [PMID: 28837958 DOI: 10.1016/j.biomaterials.2017.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
303 Chen SL, Wang GP, Shi DR, Yao SH, Chen KD, Yao HP. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. World J Gastroenterol 2021; 27(20): 2507-2520 [PMID: 34092972 DOI: 10.3748/wjg.v27.i20.2507] [Reference Citation Analysis]
304 Chen Z, Downing S, Tzanakakis ES. Four Decades After the Discovery of Regenerating Islet-Derived (Reg) Proteins: Current Understanding and Challenges. Front Cell Dev Biol. 2019;7:235. [PMID: 31696115 DOI: 10.3389/fcell.2019.00235] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
305 Tomás-Bort E, Kieler M, Sharma S, Candido JB, Loessner D. 3D approaches to model the tumor microenvironment of pancreatic cancer. Theranostics 2020;10:5074-89. [PMID: 32308769 DOI: 10.7150/thno.42441] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
306 Zhou Q, Zhou Y, Liu X, Shen Y. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Sci Rep 2017;7:13379. [PMID: 29042665 DOI: 10.1038/s41598-017-13869-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
307 He M, Henderson M, Muth S, Murphy A, Zheng L. Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Ann Pancreat Cancer 2020;3:7. [PMID: 32832900 DOI: 10.21037/apc.2020.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
308 Khorasani ABS, Sanaei MJ, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. Int Immunopharmacol 2021;101:108260. [PMID: 34678690 DOI: 10.1016/j.intimp.2021.108260] [Reference Citation Analysis]
309 Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog 2020;59:1227-40. [PMID: 32816368 DOI: 10.1002/mc.23251] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Chopra N, Choudhury S, Bhargava S, Wajid S, Ganguly NK. Potentials of "stem cell-therapy" in pancreatic cancer: An update. Pancreatology. 2019;19:1034-1042. [PMID: 31668563 DOI: 10.1016/j.pan.2019.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
311 Iacobuzio-donahue CA, Litchfield K, Swanton C. Intratumor heterogeneity reflects clinical disease course. Nat Cancer 2020;1:3-6. [DOI: 10.1038/s43018-019-0002-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
312 Gupta R, Malvi P, Parajuli KR, Janostiak R, Bugide S, Cai G, Zhu LJ, Green MR, Wajapeyee N. KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity. Proc Natl Acad Sci U S A 2020;117:12341-51. [PMID: 32430335 DOI: 10.1073/pnas.2005156117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
313 Skrypek K, Balog S, Eriguchi Y, Asahina K. Inhibition of Stearoyl-CoA Desaturase Induces the Unfolded Protein Response in Pancreatic Tumors and Suppresses Their Growth. Pancreas 2021;50:219-26. [PMID: 33565799 DOI: 10.1097/MPA.0000000000001737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Henze L, Walter U, Murua Escobar H, Junghanss C, Jaster R, Köhling R, Lange F, Salehzadeh-Yazdi A, Wolkenhauer O, Hamed M, Barrantes I, Palmer D, Möller S, Kowald A, Heussen N, Fuellen G. Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and ischaemic stroke, with focus on (co)-morbidity and ageing/cellular senescence (SASKit): protocol for a prospective cohort study. BMJ Open 2020;10:e039560. [PMID: 33334830 DOI: 10.1136/bmjopen-2020-039560] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Mahajan UM, Alnatsha A, Li Q, Oehrle B, Weiss FU, Sendler M, Distler M, Uhl W, Fahlbusch T, Goni E, Beyer G, Chromik A, Bahra M, Klein F, Pilarsky C, Grützmann R, Lerch MM, Lauber K, Christiansen N, Kamlage B, Regel I, Mayerle J. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Cells 2021;10:1821. [PMID: 34359990 DOI: 10.3390/cells10071821] [Reference Citation Analysis]
316 Gulla A, Kazlauskas E, Liang H, Strupas K, Petrauskas V, Matulis D, Eshleman JR. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Pancreas 2021;50:625-32. [PMID: 33939678 DOI: 10.1097/MPA.0000000000001807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Kuang F, Liu J, Xie Y, Tang D, Kang R. MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Cell Chem Biol 2021;28:765-775.e5. [PMID: 33539732 DOI: 10.1016/j.chembiol.2021.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
318 Avancini A, Trestini I, Tregnago D, Cavallo A, Bragato M, Bonaiuto C, Lanza M, Milella M, Pilotto S. Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. Future Sci OA 2020;7:FSO659. [PMID: 33437520 DOI: 10.2144/fsoa-2020-0165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
319 Zhou CY, Dong YP, Sun X, Sui X, Zhu H, Zhao YQ, Zhang YY, Mason C, Zhu Q, Han SX. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer Med 2018;7:5525-33. [PMID: 30358133 DOI: 10.1002/cam4.1833] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
320 Hu LP, Zhou KX, Huo YM, Liu DJ, Li Q, Yang MW, Huang PQ, Xu CJ, Tian GA, Yao LL, Zhang XL, Wang YH, Li J, Zhang ZG, Jiang SH, Xing X, Wang X, Qin WT, Yang Q. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Oncogenesis 2021;10:22. [PMID: 33658487 DOI: 10.1038/s41389-021-00311-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Shen T, Jia S, Ding G, Ping D, Zhou L, Zhou S, Cao L. BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations. iScience 2020;23:101431. [PMID: 32798974 DOI: 10.1016/j.isci.2020.101431] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
322 Balendran-Braun S, Kieler M, Liebmann-Reindl S, Unseld M, Bianconi D, W Prager G, Streubel B. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Cancer Manag Res 2021;13:6249-61. [PMID: 34393517 DOI: 10.2147/CMAR.S308029] [Reference Citation Analysis]
323 Chen Y, Ren B, Yang J, Wang H, Yang G, Xu R, You L, Zhao Y. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduct Target Ther 2020;5:143. [PMID: 32747629 DOI: 10.1038/s41392-020-00252-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
324 Huang S, Zhang X, Luo K, Jiang L, Jiang J, Li R. Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition. Front Oncol 2022;11:762233. [DOI: 10.3389/fonc.2021.762233] [Reference Citation Analysis]
325 Ismail T, Donati-Zeppa S, Akhtar S, Turrini E, Layla A, Sestili P, Fimognari C. Coffee in cancer chemoprevention: an updated review. Expert Opin Drug Metab Toxicol 2021;17:69-85. [PMID: 33074040 DOI: 10.1080/17425255.2021.1839412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
326 Robby AI, Lee G, Lee KD, Jang YC, Park SY. GSH-responsive self-healable conductive hydrogel of highly sensitive strain-pressure sensor for cancer cell detection. Nano Today 2021;39:101178. [DOI: 10.1016/j.nantod.2021.101178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
327 Recio-Boiles A, Nallagangula A, Veeravelli S, Vondrak J, Saboda K, Roe D, Elquza E, McBride A, Babiker HM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2019;2. [PMID: 31360919 DOI: 10.21037/apc.2019.06.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
328 Barbagallo M, Ciprani D, Rimassa L, Cortese N, Comito T, Spaggiari P, Marchesi F, Zerbi A. The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Pancreas 2021;50:e76-8. [PMID: 34860821 DOI: 10.1097/MPA.0000000000001907] [Reference Citation Analysis]
329 Xie L, Xia L, Klaiber U, Sachsenmaier M, Hinz U, Bergmann F, Strobel O, Büchler MW, Neoptolemos JP, Fortunato F, Hackert T. Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. Oncotarget 2019;10:7276-87. [PMID: 31921387 DOI: 10.18632/oncotarget.27399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
330 Omari J, Heinze C, Wilck A, Hass P, Seidensticker M, Seidensticker R, Mohnike K, Ricke J, Pech M, Powerski M. Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. Eur J Radiol 2019;112:22-7. [PMID: 30777214 DOI: 10.1016/j.ejrad.2018.12.020] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
331 Nowotarski HL, Attayek PJ, Allbritton NL. Automated platform for cell selection and separation based on four-dimensional motility and matrix degradation. Analyst 2020;145:2731-42. [PMID: 32083265 DOI: 10.1039/c9an02224d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Singh K, Dong Q, Timirishanmugam PS, Koul S, Koul HK. Tetrandrine inhibits deregulated cell cycle in pancreatic cancer cells: Differential regulation of p21 Cip1/Waf1 , p27 Kip1 and cyclin D1. Cancer Letters 2018;425:164-73. [DOI: 10.1016/j.canlet.2018.03.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
333 Lenggenhager D, Bengs S, Fritsch R, Hussung S, Busenhart P, Endhardt K, Töpfer A, The FO, Bütikofer S, Gubler C, Scharl M, Morell B. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Clin Transl Gastroenterol 2021;12:e00395. [PMID: 34388137 DOI: 10.14309/ctg.0000000000000395] [Reference Citation Analysis]
334 Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP, Do KA, Zhang J, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger J, Yip-Schneider MT, Maitra A, Wolpin BM, Hanash S. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology 2021;160:1373-1383.e6. [PMID: 33333055 DOI: 10.1053/j.gastro.2020.11.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
335 Matsubayashi H, Sasaki K, Ono S, Abe M, Ishiwatari H, Fukutomi A, Uesaka K, Ono H. Pathological and Molecular Aspects to Improve Endoscopic Ultrasonography-Guided Fine-Needle Aspiration From Solid Pancreatic Lesions. Pancreas 2018;47:163-72. [PMID: 29346217 DOI: 10.1097/MPA.0000000000000986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
336 Kemp SB, Pasca di Magliano M, Crawford HC. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00151-X. [PMID: 34303882 DOI: 10.1016/j.jcmgh.2021.07.006] [Reference Citation Analysis]
337 Hwang HK, Murakami T, Kiyuna T, Kim SH, Lee SH, Kang CM, Hoffman RM, Bouvet M. Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. Oncotarget 2017;8:88827-34. [PMID: 29179479 DOI: 10.18632/oncotarget.21331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
338 Martín-Blázquez A, Jiménez-Luna C, Díaz C, Martínez-Galán J, Prados J, Vicente F, Melguizo C, Genilloud O, Pérez Del Palacio J, Caba O. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers (Basel) 2020;12:E1002. [PMID: 32325731 DOI: 10.3390/cancers12041002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
339 Sunami Y, Kleeff J. Immunotherapy of pancreatic cancer. Prog Mol Biol Transl Sci 2019;164:189-216. [PMID: 31383405 DOI: 10.1016/bs.pmbts.2019.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
340 Taguchi K, Lu H, Jiang Y, Hung TT, Stenzel MH. Safety of nanoparticles based on albumin-polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy. J Mater Chem B 2018;6:6278-87. [PMID: 32254618 DOI: 10.1039/c8tb01613e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
341 Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol 2021; 27(40): 6775-6793 [PMID: 34790007 DOI: 10.3748/wjg.v27.i40.6775] [Reference Citation Analysis]
342 Mohamed E, Needham A, Psarelli E, Carroll M, Vinjamuri S, Sanghera B, Wong WL, Halloran C, Ghaneh P. Prognostic value of 18FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Eur J Surg Oncol 2020;46:1532-8. [PMID: 32070641 DOI: 10.1016/j.ejso.2020.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
343 Chen J, Yang J, Fei X, Wang X, Wang K. CircRNA ciRS-7: a Novel Oncogene in Multiple Cancers. Int J Biol Sci 2021;17:379-89. [PMID: 33390857 DOI: 10.7150/ijbs.54292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
344 Srinivasan S, Totiger T, Shi C, Castellanos J, Lamichhane P, Dosch AR, Messaggio F, Kashikar N, Honnenahally K, Ban Y, Merchant NB, VanSaun M, Nagathihalli NS. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Cancer Res 2018;78:6146-58. [PMID: 30232221 DOI: 10.1158/0008-5472.CAN-18-0579] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
345 Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Reference Citation Analysis]
346 Domoto T, Uehara M, Bolidong D, Minamoto T. Glycogen Synthase Kinase 3β in Cancer Biology and Treatment. Cells 2020;9:E1388. [PMID: 32503133 DOI: 10.3390/cells9061388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
347 Hann A, Bettac L, Haenle MM, Graeter T, Berger AW, Dreyhaupt J, Schmalstieg D, Zoller WG, Egger J. Algorithm guided outlining of 105 pancreatic cancer liver metastases in Ultrasound. Sci Rep 2017;7:12779. [PMID: 28986569 DOI: 10.1038/s41598-017-12925-z] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
348 Buanes TA. Role of surgery in pancreatic cancer. World J Gastroenterol 2017; 23(21): 3765-3770 [PMID: 28638216 DOI: 10.3748/wjg.v23.i21.3765] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
349 Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer 2019;120:848-54. [PMID: 30867564 DOI: 10.1038/s41416-019-0426-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
350 Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology 2019;46:19-27. [DOI: 10.1053/j.seminoncol.2018.12.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
351 Korc M. Pathogenesis of Pancreatic Cancer-Related Diabetes Mellitus: Quo Vadis? Pancreas 2019;48:594-7. [PMID: 31090659 DOI: 10.1097/MPA.0000000000001300] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
352 Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, Carter R, Cunningham D, Tebbutt NC, Goldstein D, Shannon J, Glimelius B, Hackert T, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Palmer DH, Büchler MW, Ghaneh P, Neoptolemos JP, Greenhalf W. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers (Basel) 2021;13:5758. [PMID: 34830914 DOI: 10.3390/cancers13225758] [Reference Citation Analysis]
353 Tuerhong A, Xu J, Shi S, Tan Z, Meng Q, Hua J, Liu J, Zhang B, Wang W, Yu X, Liang C. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Cell Mol Life Sci 2021;78:5505-26. [PMID: 34131808 DOI: 10.1007/s00018-021-03866-y] [Reference Citation Analysis]
354 Chen M, Zhou Z, Suo Y, Li M, Yao J, Peng L, Xia Y. Acyclonucleosides bearing coplanar arylethynyltriazole nucleobases: synthesis, structural analysis, and biological evaluation. New J Chem 2017;41:8509-19. [DOI: 10.1039/c7nj01406f] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
355 Wang Z, Ke N, Wang X, Wang X, Chen Y, Chen H, Liu J, He D, Tian B, Li A, Hu W, Li K, Liu X. Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study. Medicine (Baltimore) 2021;100:e26918. [PMID: 34477122 DOI: 10.1097/MD.0000000000026918] [Reference Citation Analysis]
356 Sántha P, Lenggenhager D, Finstadsveen A, Dorg L, Tøndel K, Amrutkar M, Gladhaug IP, Verbeke C. Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. Cancers (Basel) 2021;13:895. [PMID: 33672734 DOI: 10.3390/cancers13040895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
357 Tarasiuk A, Mackiewicz T, Małecka-Panas E, Fichna J. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool? Cancer Biol Ther 2021;22:347-56. [PMID: 34224317 DOI: 10.1080/15384047.2021.1941584] [Reference Citation Analysis]
358 Birgin E, Rasbach E, Téoule P, Rückert F, Reissfelder C, Rahbari NN. Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. Sci Rep 2020;10:22178. [PMID: 33335201 DOI: 10.1038/s41598-020-79252-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Schipper J, Westerhuis JJ, Beddows I, Madaj Z, Monsma D, Hostetter G, Kiupel M, Conejo-Garcia JR, Sempere LF. Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. Int J Cancer 2020;147:2265-78. [PMID: 32388866 DOI: 10.1002/ijc.33041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
360 Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, He S, Shimamoto F. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer 2020;19:3. [PMID: 31906946 DOI: 10.1186/s12943-019-1128-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 31.0] [Reference Citation Analysis]
361 Beizavi Z, Gheibihayat SM, Moghadasian H, Zare H, Yeganeh BS, Askari H, Vakili S, Tajbakhsh A, Savardashtaki A. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy? Mol Biol Rep 2021;48:5707-22. [PMID: 34275112 DOI: 10.1007/s11033-021-06547-y] [Reference Citation Analysis]
362 Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Sivinski J, Chauhan SS, Seshadri M, Abrams SI, Wang J, Witkiewicz AK. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut 2021;70:127-38. [PMID: 32424005 DOI: 10.1136/gutjnl-2020-321000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
363 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
364 Asahina K, Balog S, Hwang E, Moon E, Wan E, Skrypek K, Chen Y, Fernandez J, Romo J, Yang Q, Lai K, French SW, Tsukamoto H. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras. Am J Physiol Gastrointest Liver Physiol 2020;318:G265-76. [PMID: 31760766 DOI: 10.1152/ajpgi.00218.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
365 Marzan AL, Stewart SE. Elucidating the Role of Extracellular Vesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:5669. [PMID: 34830825 DOI: 10.3390/cancers13225669] [Reference Citation Analysis]
366 Liu Q, Wu H, Li Y, Zhang R, Kleeff J, Zhang X, Cui M, Liu J, Li T, Gao J, Pan B, Wu W, Wang W, Zhou L, Guo J, Dai M, Zhang T, Liao Q, Lu Z, Zhao Y. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunol Immunother 2020;69:1477-92. [PMID: 32285172 DOI: 10.1007/s00262-020-02542-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
367 Niesen W, Primavesi F, Gasteiger S, Neoptolemos J, Hackert T, Stättner S. Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. Eur Surg 2019;51:153-64. [DOI: 10.1007/s10353-019-0589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
368 Gimotty PA, Till JE, Udgata S, Takenaka N, Yee SS, LaRiviere MJ, O'Hara MH, Reiss KA, O'Dwyer P, Katona BW, Herman D, Carpenter EL, Zaret KS. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Oncotarget 2021;12:2266-72. [PMID: 34733417 DOI: 10.18632/oncotarget.28099] [Reference Citation Analysis]
369 Amrutkar M, Gladhaug IP. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer. Cancers (Basel) 2021;13:601. [PMID: 33546284 DOI: 10.3390/cancers13040601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
370 Mameishvili E, Serafimidis I, Iwaszkiewicz S, Lesche M, Reinhardt S, Bölicke N, Büttner M, Stellas D, Papadimitropoulou A, Szabolcs M, Anastassiadis K, Dahl A, Theis F, Efstratiadis A, Gavalas A. Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer. Proc Natl Acad Sci U S A 2019;116:20679-88. [PMID: 31548432 DOI: 10.1073/pnas.1901075116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
371 Novak I, Yu H, Magni L, Deshar G. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer. Int J Mol Sci 2020;21:E8781. [PMID: 33233631 DOI: 10.3390/ijms21228781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
372 Yang J, Qi M, Fei X, Wang X, Wang K. LncRNA H19: A novel oncogene in multiple cancers. Int J Biol Sci 2021;17:3188-208. [PMID: 34421359 DOI: 10.7150/ijbs.62573] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Root A, Allen P, Tempst P, Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel) 2018;10:E67. [PMID: 29518918 DOI: 10.3390/cancers10030067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
374 Heiberg T, Baekelandt B, Kvien TK, Buanes T. Psychometric performance of the PAncreatic CAncer disease impact (PACADI) score. Pancreatology 2019;19:971-8. [PMID: 31530448 DOI: 10.1016/j.pan.2019.09.001] [Reference Citation Analysis]
375 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130:4704-4709. [PMID: 32749238 DOI: 10.1172/jci136760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
376 Long NP, Jung KH, Anh NH, Yan HH, Nghi TD, Park S, Yoon SJ, Min JE, Kim HM, Lim JH, Kim JM, Lim J, Lee S, Hong SS, Kwon SW. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. Cancers (Basel) 2019;11:E155. [PMID: 30700038 DOI: 10.3390/cancers11020155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
377 Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum Genet 2021;140:725-46. [PMID: 33180176 DOI: 10.1007/s00439-020-02235-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
378 Feng Z, Li K, Lou J, Wu Y, Peng C. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Front Cell Dev Biol 2021;9:665161. [PMID: 33996821 DOI: 10.3389/fcell.2021.665161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
379 Wang L, Yang L, Chen L, Chen Z. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis. Med Sci Monit 2019;25:8230-41. [PMID: 31677259 DOI: 10.12659/MSM.917106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
380 Hu D, Ansari D, Zhou Q, Sasor A, Said Hilmersson K, Andersson R. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. Scand J Gastroenterol 2019;54:95-100. [PMID: 30663442 DOI: 10.1080/00365521.2018.1561937] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
381 Luo Y, Yan B, Liu L, Yin L, Ji H, An X, Gladkich J, Qi Z, De La Torre C, Herr I. Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression. Cancers (Basel) 2021;13:827. [PMID: 33669381 DOI: 10.3390/cancers13040827] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
382 Yoshida A, Kitayama Y, Kiguchi K, Yamada T, Akasaka H, Sasaki R, Takeuchi T. Gold Nanoparticle-Incorporated Molecularly Imprinted Microgels as Radiation Sensitizers in Pancreatic Cancer. ACS Appl Bio Mater 2019;2:1177-83. [DOI: 10.1021/acsabm.8b00766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
383 Uher O, Caisova V, Padoukova L, Kvardova K, Masakova K, Lencova R, Frejlachova A, Skalickova M, Venhauerova A, Chlastakova A, Hansen P, Chmelar J, Kopecky J, Zhuang Z, Pacak K, Zenka J. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunol Immunother 2021. [PMID: 33855601 DOI: 10.1007/s00262-021-02920-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 He QR, Tang JJ, Liu Y, Chen ZF, Liu YX, Chen H, Li D, Yi ZF, Gao JM. The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. Br J Pharmacol 2021;178:2496-515. [PMID: 33687738 DOI: 10.1111/bph.15435] [Reference Citation Analysis]
385 Hong E, Park S, Ooshima A, Hong CP, Park J, Heo JS, Lee S, An H, Kang JM, Park SH, Park JO, Kim SJ. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. Sci Rep 2020;10:2935. [PMID: 32076068 DOI: 10.1038/s41598-020-59893-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
386 Vaish U, Jain T, Are AC, Dudeja V. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Int J Mol Sci 2021;22:13408. [PMID: 34948209 DOI: 10.3390/ijms222413408] [Reference Citation Analysis]
387 Semaan A, Maitra A. Rebooting pancreatic cancer knowledge and treatment options. Nat Rev Gastroenterol Hepatol 2018;15:76-8. [DOI: 10.1038/nrgastro.2017.182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
388 Luo Q, Fu Q, Zhang X, Zhang H, Qin T. Application of Single-Cell RNA Sequencing in Pancreatic Cancer and the Endocrine Pancreas. Adv Exp Med Biol 2020;1255:143-52. [PMID: 32949397 DOI: 10.1007/978-981-15-4494-1_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Brown JA, Zenati MS, Simmons RL, Al Abbas AI, Chopra A, Smith K, Lee KKW, Hogg ME, Zeh HJ, Paniccia A, Zureikat AH. Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk Factors.J Gastrointest Surg. 2020;24:1581-1589. [PMID: 32410174 DOI: 10.1007/s11605-020-04641-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
390 Bochner F, Mohan V, Zinger A, Golani O, Schroeder A, Sagi I, Neeman M. Intravital imaging of vascular anomalies and extracellular matrix remodeling in orthotopic pancreatic tumors. Int J Cancer 2020;146:2209-17. [PMID: 31661557 DOI: 10.1002/ijc.32759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Zhang Y, Wei Y, Liu P, Zhang X, Xu Z, Tan X, Chen M, Wang J. ICP-MS and Photothermal Dual-Readout Assay for Ultrasensitive and Point-of-Care Detection of Pancreatic Cancer Exosomes. Anal Chem 2021;93:11540-6. [PMID: 34369746 DOI: 10.1021/acs.analchem.1c02004] [Reference Citation Analysis]
392 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-348. [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x] [Cited by in Crossref: 295] [Cited by in F6Publishing: 288] [Article Influence: 98.3] [Reference Citation Analysis]
393 Jiang J, Bai J, Qin T, Wang Z, Han L. NGF from pancreatic stellate cells induces pancreatic cancer proliferation and invasion by PI3K/AKT/GSK signal pathway. J Cell Mol Med 2020;24:5901-10. [PMID: 32294802 DOI: 10.1111/jcmm.15265] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
394 Chiaravalli M, Reni M, O'reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews 2017;60:32-43. [DOI: 10.1016/j.ctrv.2017.08.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
395 Yong LK, Lai S, Liang Z, Poteet E, Chen F, van Buren G, Fisher W, Mo Q, Chen C, Yao Q. Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. Oncotarget 2016;7:87431-48. [PMID: 27911862 DOI: 10.18632/oncotarget.13704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
396 Song M, Yoon SB, Lee IS, Hong TH, Choi HJ, Choi MH, Lee MA, Jung ES, Choi MG. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? Eur J Cancer. 2018;104:62-69. [PMID: 30326370 DOI: 10.1016/j.ejca.2018.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
397 Galeotti AA, Gentiluomo M, Rizzato C, Obazee O, Neoptolemos JP, Pasquali C, Nentwich M, Cavestro GM, Pezzilli R, Greenhalf W, Holleczek B, Schroeder C, Schöttker B, Ivanauskas A, Ginocchi L, Key TJ, Hegyi P, Archibugi L, Darvasi E, Basso D, Sperti C, Bijlsma MF, Palmieri O, Hlavac V, Talar-Wojnarowska R, Mohelnikova-Duchonova B, Hackert T, Vashist Y, Strouhal O, van Laarhoven H, Tavano F, Lovecek M, Dervenis C, Izbéki F, Padoan A, Małecka-Panas E, Maiello E, Vanella G, Capurso G, Izbicki JR, Theodoropoulos GE, Jamroziak K, Katzke V, Kaaks R, Mambrini A, Papanikolaou IS, Szmola R, Szentesi A, Kupcinskas J, Bursi S, Costello E, Boggi U, Milanetto AC, Landi S, Gazouli M, Vodickova L, Soucek P, Gioffreda D, Gemignani F, Brenner H, Strobel O, Büchler M, Vodicka P, Paiella S, Canzian F, Campa D. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet 2021;58:369-77. [PMID: 32591343 DOI: 10.1136/jmedgenet-2020-106961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
398 Malik AK, Lamarca A, Siriwardena AK, O'reilly D, Deshpande R, Satyadas T, Jamdar S, Sheen A, Mcnamara M, Hubner R, Valle J, De Liguori Carino N. The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Pancreas 2020;49:201-7. [DOI: 10.1097/mpa.0000000000001486] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
399 Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 2021:S0092-8674(21)00879-5. [PMID: 34388391 DOI: 10.1016/j.cell.2021.07.020] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
400 Neoptolemos JP, Halloran CM, Ghaneh P, Kleeff J. Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders? Annals of Surgery 2018;267:e35-6. [DOI: 10.1097/sla.0000000000002026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
401 Naito Y, Ishikawa H, Sadashima E, Okabe Y, Takahashi K, Kawahara R, Hisaka T, Fukahori M, Ushijima T, Ishida Y, Tanigawa M, Mihara Y, Nakayama M, Kondo R, Kusano H, Takase Y, Abe H, Ogo E, Okuda K, Shimamatsu K, Yano H, Akiba J. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis. Mol Clin Oncol 2019;11:225-33. [PMID: 31423309 DOI: 10.3892/mco.2019.1885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Shimizu K, Hashimoto D, Umezaki N, Nakagawa S, Yamamura K, Chikamoto A, Matsumura F, Baba H. Thoracic wall muscle metastasis from pancreatic cancer. Surg Case Rep 2018;4:12. [PMID: 29372347 DOI: 10.1186/s40792-017-0393-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
403 Hu H, Qu C, Tang B, Liu W, Ma Y, Chen Y, Xie X, Zhuang Y, Gao H, Tian X, Yang Y. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis. Chin J Cancer Res 2021;33:457-69. [PMID: 34584371 DOI: 10.21147/j.issn.1000-9604.2021.04.03] [Reference Citation Analysis]
404 Hinzman CP, Aljehane L, Brown-Clay JD, Kallakury B, Sonahara F, Goel A, Trevino J, Banerjee PP. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC. Carcinogenesis 2018;39:1548-59. [PMID: 30165468 DOI: 10.1093/carcin/bgy114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
405 Elaskandrany M, Patel R, Patel M, Miller G, Saxena D, Saxena A. Fungi, host immune response, and tumorigenesis. Am J Physiol Gastrointest Liver Physiol 2021;321:G213-22. [PMID: 34231392 DOI: 10.1152/ajpgi.00025.2021] [Reference Citation Analysis]
406 Li Y, Wu J, Wang J, Hu X, Cai J, Xiang D. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomaterialia 2020;101:519-30. [DOI: 10.1016/j.actbio.2019.10.022] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 22.5] [Reference Citation Analysis]
407 Xie ZB, Zhang YF, Jin C, Mao YS, Fu DL. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. J Exp Clin Cancer Res 2019;38:75. [PMID: 30760292 DOI: 10.1186/s13046-019-1088-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
408 Zhou C, Li H, Han X, Pang H, Wu M, Tang Y, Luo X. Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy. J Invest Surg 2021;:1-17. [PMID: 33525943 DOI: 10.1080/08941939.2020.1863527] [Reference Citation Analysis]
409 Wang J, Chai J, Liu L, Cui Z, Duan D, Shi R, Zhang Y. Dual-functional melanin-based nanoliposomes for combined chemotherapy and photothermal therapy of pancreatic cancer. RSC Adv 2019;9:3012-9. [DOI: 10.1039/c8ra09420a] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
410 Jonckheere N, Van Seuningen I. Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas. J Transl Med 2018;16:259. [PMID: 30236127 DOI: 10.1186/s12967-018-1632-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
411 Erdem S, Bolli M, Müller SA, von Flüe M, White R, Worni M. Role of lymphadenectomy in resectable pancreatic cancer. Langenbecks Arch Surg 2020;405:889-902. [PMID: 32902706 DOI: 10.1007/s00423-020-01980-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Jin Y, Zhang Z, Zou S, Li F, Chen H, Peng C, Deng X, Wen C, Shen B, Zhan Q. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Front Oncol 2021;11:634881. [PMID: 33816276 DOI: 10.3389/fonc.2021.634881] [Reference Citation Analysis]
413 Wang K, Zhou W, Meng P, Wang P, Zhou C, Yao Y, Wu S, Wang Y, Zhao J, Zou D, Jin G. Immune-related somatic mutation genes are enriched in PDACs with diabetes. Transl Oncol 2019;12:1147-54. [PMID: 31203147 DOI: 10.1016/j.tranon.2019.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
414 Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS, Witkiewicz AK. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene 2019;38:3355-70. [PMID: 30696953 DOI: 10.1038/s41388-018-0650-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
415 Raviv NV, Sakhuja S, Schlachter M, Akinyemiju T. Metabolic syndrome and in-hospital outcomes among pancreatic cancer patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2017;11:S643-50. [DOI: 10.1016/j.dsx.2017.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
416 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
417 Qiu B, Zhang X, Tsauo J, Zhao H, Gong T, Li J, Li X. Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review. Abdom Radiol (NY) 2019;44:2801-8. [PMID: 31025067 DOI: 10.1007/s00261-019-02022-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
418 Paroha S, Verma J, Dubey RD, Dewangan RP, Molugulu N, Bapat RA, Sahoo PK, Kesharwani P. Recent advances and prospects in gemcitabine drug delivery systems. International Journal of Pharmaceutics 2021;592:120043. [DOI: 10.1016/j.ijpharm.2020.120043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
419 Ashraf MI. Role of Staging Laparoscopy in Patients Undergoing Pancreaticoduodenectomy. Cureus 2019;11:e5906. [PMID: 31777693 DOI: 10.7759/cureus.5906] [Reference Citation Analysis]
420 Wang J, Jin W, Zhou X, Li J, Xu C, Ma Z, Wang J, Qin L, Zhou B, Ding W, Gao T, Yao H, Chen Z. Identification, Structure-Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy. J Med Chem 2020;63:12978-91. [PMID: 33100009 DOI: 10.1021/acs.jmedchem.0c01271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
421 Solaini L, de Rooij T, Marsman EM, te Riele WW, Tanis PJ, van Gulik TM, Gouma DJ, Bhayani NH, Hackert T, Busch OR, Besselink MG. Pancreatoduodenectomy with colon resection for pancreatic cancer: a systematic review. HPB 2018;20:881-7. [DOI: 10.1016/j.hpb.2018.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
422 Amrutkar M, Aasrum M, Verbeke CS, Gladhaug IP. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer 2019;19:596. [PMID: 31208372 DOI: 10.1186/s12885-019-5803-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
423 Smolinska A, Swoboda J, Fendler W, Lerch MM, Sendler M, Moskwa P. MiR-502 is the first reported miRNA simultaneously targeting two components of the classical non-homologous end joining (C-NHEJ) in pancreatic cell lines. Heliyon 2020;6:e03187. [PMID: 32042960 DOI: 10.1016/j.heliyon.2020.e03187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
424 Tanaka T, Okada R, Hozaka Y, Wada M, Moriya S, Satake S, Idichi T, Kurahara H, Ohtsuka T, Seki N. Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes. Cancers (Basel) 2020;12:E2731. [PMID: 32977589 DOI: 10.3390/cancers12102731] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
425 Hernandez R, England CG, Yang Y, Valdovinos HF, Liu B, Wong HC, Barnhart TE, Cai W. ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836. J Control Release. 2017;264:160-168. [PMID: 28843831 DOI: 10.1016/j.jconrel.2017.08.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
426 Takagi K, Shimomura A, Imura J, Mori H, Noguchi A, Tanaka S, Minamisaka T, Nishida T, Hatta H, Nakajima T. Interleukin-32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells. Oncol Lett 2022;23:14. [PMID: 34820013 DOI: 10.3892/ol.2021.13132] [Reference Citation Analysis]
427 Lin CC, Korc M. Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment. Cancer Lett 2018;436:22-7. [PMID: 30118843 DOI: 10.1016/j.canlet.2018.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
428 He S, Dong G, Li Y, Wu S, Wang W, Sheng C. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angew Chem 2020;132:3052-6. [DOI: 10.1002/ange.201915896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Li SS, Zhou CY, Liao R, Xiong L, Weng NN, Zhao YQ, Mason C, Gou HF, Yi C, Zhu Q. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2020;99:e19413. [PMID: 32243360 DOI: 10.1097/MD.0000000000019413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
431 Courtney PT, Paravati AJ, Atwood TF, Raja N, Zimmerman CT, Fanta PT, Lowy AM, Simpson DR, Xu R, Murphy JD. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2021;110:1003-12. [PMID: 33571625 DOI: 10.1016/j.ijrobp.2021.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Pizzato M, Turati F, Rosato V, La Vecchia C. Exploring the link between diabetes and pancreatic cancer. Expert Rev Anticancer Ther 2019;19:681-7. [PMID: 31287962 DOI: 10.1080/14737140.2019.1642109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
433 Ge JC, Tao M, Li L, Ma ZL, Jiang B, Yuan CH, Wang HY, Peng Y, Xiu DR. Nomogram and competing risk model to predict recurrence after curative surgical resection of PDAC. Pancreatology 2021:S1424-3903(21)00149-6. [PMID: 34001437 DOI: 10.1016/j.pan.2021.04.010] [Reference Citation Analysis]
434 Lv K, Yang J, Sun J, Guan J. Identification of key candidate genes for pancreatic cancer by bioinformatics analysis. Exp Ther Med 2019;18:451-8. [PMID: 31281439 DOI: 10.3892/etm.2019.7619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
435 Tong QS, Miao WM, Huang H, Luo JQ, Liu R, Huang YC, Zhao DK, Shen S, Du JZ, Wang J. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer. Small 2021;17:e2101208. [PMID: 34145747 DOI: 10.1002/smll.202101208] [Reference Citation Analysis]
436 Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34331036 DOI: 10.1038/s41575-021-00486-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
437 Kalinin S, Malkova A, Sharonova T, Sharoyko V, Bunev A, Supuran CT, Krasavin M. Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors. Int J Mol Sci 2021;22:13405. [PMID: 34948200 DOI: 10.3390/ijms222413405] [Reference Citation Analysis]
438 Ding Z, Gu Y, Huang D, Zhou H, Zhu T, Luo X, Zhang S, Zhang S, Qian Y. Cholesterol biosynthesis inhibitor RO 48‑8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway. Mol Med Rep 2021;24:828. [PMID: 34590153 DOI: 10.3892/mmr.2021.12468] [Reference Citation Analysis]
439 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. LncRNA DiGeorge syndrome critical region gene 5: A crucial regulator in malignant tumors. Biomed Pharmacother 2021;141:111889. [PMID: 34323697 DOI: 10.1016/j.biopha.2021.111889] [Reference Citation Analysis]
440 Foulkes R, Ali Asgari M, Curtis A, Hoskins C. Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer. ACS Appl Nano Mater 2019;2:1758-72. [DOI: 10.1021/acsanm.9b00439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
441 Chung MJ, Park SW, Kim SH, Cho CM, Choi JH, Choi EK, Lee TH, Cho E, Lee JK, Song TJ, Lee JM, Son JH, Park JS, Oh CH, Park DA, Byeon JS, Lee ST, Kim HG, Chun HJ, Choi HS, Park CG, Cho JY. Clinical and Technical Guideline for Endoscopic Ultrasound (EUS)-Guided Tissue Acquisition of Pancreatic Solid Tumor: Korean Society of Gastrointestinal Endoscopy (KSGE). Gut Liver 2021;15:354-74. [PMID: 33767027 DOI: 10.5009/gnl20302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Vetvicka D, Sivak L, Jogdeo CM, Kumar R, Khan R, Hang Y, Oupický D. Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next? J Control Release 2021;331:246-59. [PMID: 33482273 DOI: 10.1016/j.jconrel.2021.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
443 Lin J, Chen S, Lu C, Lin J, Yen G. Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine‐resistant human pancreatic cancer cells. Phytotherapy Research 2020;34:2053-66. [DOI: 10.1002/ptr.6669] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
444 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
445 Purohit V, Wang L, Yang H, Li J, Ney GM, Gumkowski ER, Vaidya AJ, Wang A, Bhardwaj A, Zhao E, Dolgalev I, Zamperone A, Abel EV, Magliano MPD, Crawford HC, Diolaiti D, Papagiannakopoulos TY, Lyssiotis CA, Simeone DM. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Genes Dev 2021;35:218-33. [PMID: 33446568 DOI: 10.1101/gad.344184.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Jiraskova L, Ryska A, Duintjer Tebbens EJ, Hornychova H, Cecka F, Staud F, Cerveny L. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers (Basel) 2019;11:E1621. [PMID: 31652721 DOI: 10.3390/cancers11111621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Weng CC, Lin YC, Cheng KH. The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer. J Clin Med 2019;8:E1369. [PMID: 31480737 DOI: 10.3390/jcm8091369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
448 Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018;10:E24. [PMID: 29361690 DOI: 10.3390/cancers10010024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
449 Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-220. [PMID: 30718832 DOI: 10.1038/s41575-019-0109-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 176] [Article Influence: 68.0] [Reference Citation Analysis]
450 Ghanaatgar-kasbi S, Khorrami S, Avan A, Aledavoud SA, Ferns GA. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. CPD 2019;24:4619-25. [DOI: 10.2174/1381612825666190110145855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
451 Klaiber U, Roth S, Hackert T, Neoptolemos JP. Evolution of oncosurgical management of pancreatic cancer. Eur Surg 2019;51:165-73. [DOI: 10.1007/s10353-019-0587-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
452 Uddin MH, Al-Hallak MN, Philip PA, Mohammad RM, Viola N, Wagner KU, Azmi AS. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers (Basel) 2021;13:2777. [PMID: 34204940 DOI: 10.3390/cancers13112777] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
453 Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019;26:619-27. [PMID: 30324485 DOI: 10.1245/s10434-018-6807-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
454 Rodriguez Lanzi C, Wei R, Luo D, Mackenzie GG. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. Neoplasia 2021;24:133-44. [PMID: 34968866 DOI: 10.1016/j.neo.2021.12.004] [Reference Citation Analysis]
455 Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. PLoS One 2020;15:e0226707. [PMID: 31923206 DOI: 10.1371/journal.pone.0226707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
456 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer 2018;118:947-54. [PMID: 29515256 DOI: 10.1038/s41416-018-0004-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
457 Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS; ETCTN-9231 Study Team. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clin Transl Sci 2020;13:1178-88. [PMID: 32738099 DOI: 10.1111/cts.12802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
458 Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg 2019;269:520-9. [PMID: 29068800 DOI: 10.1097/SLA.0000000000002557] [Cited by in Crossref: 95] [Cited by in F6Publishing: 48] [Article Influence: 31.7] [Reference Citation Analysis]
459 Papalazarou V, Salmeron-Sanchez M, Machesky LM. Tissue engineering the cancer microenvironment-challenges and opportunities. Biophys Rev 2018;10:1695-711. [PMID: 30406572 DOI: 10.1007/s12551-018-0466-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
460 Pourhanifeh MH, Mehrzadi S, Kamali M, Hosseinzadeh A. Melatonin and gastrointestinal cancers: Current evidence based on underlying signaling pathways. Eur J Pharmacol 2020;886:173471. [PMID: 32877658 DOI: 10.1016/j.ejphar.2020.173471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
461 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1-10. [PMID: 29564165 DOI: 10.21037/jgo.2017.10.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
462 Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Front Immunol 2018;9:1878. [PMID: 30158932 DOI: 10.3389/fimmu.2018.01878] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
463 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Reference Citation Analysis]
464 Bai M, Zheng Y, Liu H, Su B, Zhan Y, He H. CXCR5+ CD8+ T cells potently infiltrate pancreatic tumors and present high functionality. Exp Cell Res 2017;361:39-45. [PMID: 28965867 DOI: 10.1016/j.yexcr.2017.09.039] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
465 Xu R, Yang J, Ren B, Wang H, Yang G, Chen Y, You L, Zhao Y. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Front Oncol 2020;10:572722. [PMID: 33117704 DOI: 10.3389/fonc.2020.572722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
466 Tong Z, Liu Y, Ma H, Zhang J, Lin B, Bao X, Xu X, Gu C, Zheng Y, Liu L, Fang W, Deng S, Zhao P. Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer. Front Bioeng Biotechnol 2020;8:196. [PMID: 32232040 DOI: 10.3389/fbioe.2020.00196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
467 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020;38:3185-94. [PMID: 32706635 DOI: 10.1200/JCO.20.00590] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
468 Song L, Qi S, Hu W, Fang Z, Yu D, Liu T, Wu J, Wu Y, Wu A, Feng L, Xie J, Zhang B, He W, Ning Z, Liu L, Qin JJ, Li S. Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Mol Ther Nucleic Acids 2021;26:11-21. [PMID: 34513290 DOI: 10.1016/j.omtn.2021.06.015] [Reference Citation Analysis]
469 Sempere LF, Powell K, Rana J, Brock AA, Schmittgen TD. Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer. Cancer Metastasis Rev 2021;40:761-76. [PMID: 34591242 DOI: 10.1007/s10555-021-09995-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
470 Galvano A, Castiglia M, Rizzo S, Silvestris N, Brunetti O, Vaccaro G, Gristina V, Barraco N, Bono M, Guercio G, Graceffa G, Fulfaro F, Gori S, Bazan V, Russo A. Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.Cancers (Basel). 2020;12. [PMID: 32110977 DOI: 10.3390/cancers12030534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
471 Vucetic M, Daher B, Cassim S, Parks S, Pouyssegur J. Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. Adv Exp Med Biol 2021;1301:7-24. [PMID: 34370285 DOI: 10.1007/978-3-030-62026-4_2] [Reference Citation Analysis]
472 Paoli C, Carrer A. Organotypic Culture of Acinar Cells for the Study of Pancreatic Cancer Initiation. Cancers (Basel) 2020;12:E2606. [PMID: 32932616 DOI: 10.3390/cancers12092606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Yamada R, Isaji S, Fujii T, Mizuno S, Kishiwada M, Murata Y, Hayasaki A, Inoue H, Umeda Y, Tanaka K, Hamada Y, Tsuboi J, Kato T, Kondo Y, Matsuda S, Watanabe N, Ogura T, Tamaru S. Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. JMIR Res Protoc 2021;10:e26898. [PMID: 34677132 DOI: 10.2196/26898] [Reference Citation Analysis]
474 Ajina R, Weiner LM. T-Cell Immunity in Pancreatic Cancer. Pancreas 2020;49:1014-23. [PMID: 32833941 DOI: 10.1097/MPA.0000000000001621] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
475 Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Dhawan M, Kulkarni A, Thakkar S. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy. J Gastrointest Cancer 2020;51:836-43. [PMID: 31605289 DOI: 10.1007/s12029-019-00303-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
476 Suzuki SR, Kuno A, Ozaki H. Cell-to-cell interaction analysis of prognostic ligand-receptor pairs in human pancreatic ductal adenocarcinoma. Biochem Biophys Rep 2021;28:101126. [PMID: 34522794 DOI: 10.1016/j.bbrep.2021.101126] [Reference Citation Analysis]
477 Feng Z, Qian H, Li K, Lou J, Wu Y, Peng C. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:676291. [PMID: 34095229 DOI: 10.3389/fmolb.2021.676291] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
478 Ren W, Xourafas D, Ashley SW, Clancy TE. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. J Surg Res 2021;257:605-15. [PMID: 32947122 DOI: 10.1016/j.jss.2020.07.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Hosein AN, Huang H, Wang Z, Parmar K, Du W, Huang J, Maitra A, Olson E, Verma U, Brekken RA. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight 2019;5:129212. [PMID: 31335328 DOI: 10.1172/jci.insight.129212] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 16.3] [Reference Citation Analysis]
480 Chen H, Weng Z, Xu C. Albendazole suppresses cell proliferation and migration and induces apoptosis in human pancreatic cancer cells. Anticancer Drugs 2020;31:431-9. [PMID: 32044795 DOI: 10.1097/CAD.0000000000000914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
481 Kryklyva V, Ter Linden E, Kroeze LI, de Voer RM, van der Kolk BM, Stommel MWJ, Hermans JJ, Luchini C, Wood LD, Hruban RH, Nagtegaal ID, Ligtenberg MJL, Brosens LAA. Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival. Pancreas 2020;49:999-1003. [PMID: 32658072 DOI: 10.1097/MPA.0000000000001588] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
482 [DOI: 10.1101/2020.07.28.225813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
483 Gao Y, Chen S, Sun J, Su S, Yang D, Xiang L, Meng X. Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: A review. Phytother Res 2021;35:603-28. [PMID: 32965773 DOI: 10.1002/ptr.6847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
484 Usai A, Di Franco G, Piccardi M, Cateni P, Pollina LE, Vivaldi C, Vasile E, Funel N, Palmeri M, Dente L, Falcone A, Giunchi D, Massolo A, Raffa V, Morelli L. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel) 2021;13:4131. [PMID: 34439284 DOI: 10.3390/cancers13164131] [Reference Citation Analysis]
485 Hirai K, Watanabe S, Nishijima N, Shibata K, Hase A, Yamanaka T, Inazu M. Molecular and Functional Analysis of Choline Transporters and Antitumor Effects of Choline Transporter-Like Protein 1 Inhibitors in Human Pancreatic Cancer Cells. Int J Mol Sci 2020;21:E5190. [PMID: 32707889 DOI: 10.3390/ijms21155190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
486 Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 2019;13:1623-50. [PMID: 31243883 DOI: 10.1002/1878-0261.12537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
487 Chung MJ, Park SW, Kim SH, Cho CM, Choi JH, Choi EK, Lee TH, Cho E, Lee JK, Song TJ, Lee JM, Son JH, Park JS, Oh CH, Park DA, Byeon JS, Lee ST, Kim HG, Chun HJ, Choi HS, Park CG, Cho JY. [Clinical and Technical Guideline for Endoscopic Ultrasound-guided Tissue Acquisition of Pancreatic Solid Tumor: Korean Society of Gastrointestinal Endoscopy]. Korean J Gastroenterol 2021;78:73-93. [PMID: 34446631 DOI: 10.4166/kjg.2021.057] [Reference Citation Analysis]
488 Saha A, Zhao S, Chen Z, Georgiou G, Stone E, Kidane D, DiGiovanni J. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. Mol Ther 2021;29:775-87. [PMID: 33091613 DOI: 10.1016/j.ymthe.2020.10.016] [Reference Citation Analysis]
489 Huart C, Chen JW, Le Calvé B, Michiels C, Wéra AC. Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer? Int J Mol Sci 2020;21:E4767. [PMID: 32635552 DOI: 10.3390/ijms21134767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
490 Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A, Schmid MC. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res. 2018;78:4253-4269. [PMID: 29789416 DOI: 10.1158/0008-5472.can-17-3876] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
491 Menini S, Iacobini C, Vitale M, Pesce C, Pugliese G. Diabetes and Pancreatic Cancer-A Dangerous Liaison Relying on Carbonyl Stress. Cancers (Basel). 2021;13. [PMID: 33467038 DOI: 10.3390/cancers13020313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
492 Roth HE, Bhinderwala F, Franco R, Zhou Y, Powers R. DNAJA1 Dysregulates Metabolism Promoting an Antiapoptotic Phenotype in Pancreatic Ductal Adenocarcinoma. J Proteome Res 2021;20:3925-39. [PMID: 34264680 DOI: 10.1021/acs.jproteome.1c00233] [Reference Citation Analysis]
493 Adjuto-Saccone M, Soubeyran P, Garcia J, Audebert S, Camoin L, Rubis M, Roques J, Binétruy B, Iovanna JL, Tournaire R. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death Dis 2021;12:649. [PMID: 34172716 DOI: 10.1038/s41419-021-03920-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
494 Mollinedo F, Gajate C. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers (Basel) 2021;13:4173. [PMID: 34439330 DOI: 10.3390/cancers13164173] [Reference Citation Analysis]
495 Azzariti A, Iacobazzi RM, Di Fonte R, Porcelli L, Gristina R, Favia P, Fracassi F, Trizio I, Silvestris N, Guida G, Tommasi S, Sardella E. Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Sci Rep 2019;9:4099. [PMID: 30858524 DOI: 10.1038/s41598-019-40637-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 17.3] [Reference Citation Analysis]
496 Lian M, Wang Q, Jiang X, Zhang J, Wei Y, Li Y, Li B, Chen W, Zhang H, Miao Q, Peng Y, Xiao X, Sheng L, Zhang W, Fang J, Tang R, Gershwin ME, Ma X. The Immunobiology of Receptor Activator for Nuclear Factor Kappa B Ligand and Myeloid‐Derived Suppressor Cell Activation in Immunoglobulin G4–Related Sclerosing Cholangitis. Hepatology 2018;68:1922-36. [DOI: 10.1002/hep.30095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
497 Tartaglione S, Mancini P, Viggiani V, Chirletti P, Angeloni A, Anastasi E. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. PLoS One 2021;16:e0251656. [PMID: 34015010 DOI: 10.1371/journal.pone.0251656] [Reference Citation Analysis]
498 Gu J, Huang W, Zhang J, Wang X, Tao T, Yang L, Zheng Y, Liu S, Yang J, Zhu L, Wang H, Fan Y. TMPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway. Front Oncol 2021;11:628353. [PMID: 33816264 DOI: 10.3389/fonc.2021.628353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Mizuno S, Nakai Y, Ishigaki K, Saito K, Oyama H, Hamada T, Suzuki Y, Inokuma A, Kanai S, Noguchi K, Sato T, Hakuta R, Saito T, Takahara N, Kogure H, Isayama H, Koike K. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Diagnostics (Basel) 2020;10:E572. [PMID: 32784500 DOI: 10.3390/diagnostics10080572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
500 Cai H, Chen Y, Xu L, Zou Y, Zhou X, Liang G, Wang D, Tao Z. Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Front Bioeng Biotechnol 2021;9:699610. [PMID: 34268300 DOI: 10.3389/fbioe.2021.699610] [Reference Citation Analysis]
501 Chen B, Deng T, Deng L, Yu H, He B, Chen K, Zheng C, Wang D, Wang Y, Chen G. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. BMC Cancer 2021;21:1211. [PMID: 34772375 DOI: 10.1186/s12885-021-08962-7] [Reference Citation Analysis]
502 Görte J, Danen E, Cordes N. Therapy-Naïve and Radioresistant 3-Dimensional Pancreatic Cancer Cell Cultures Are Effectively Radiosensitized by β1 Integrin Targeting. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02728-0. [PMID: 34481933 DOI: 10.1016/j.ijrobp.2021.08.035] [Reference Citation Analysis]
503 Mork M, Quesada PR, Bannon S, Montiel MF, Fleming JB, Lynch PM, Bhutani MS, Lee JH, McAllister F. Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome. Pancreas 2019;48:e29-30. [PMID: 30973470 DOI: 10.1097/MPA.0000000000001293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
504 Kjaergaard AD, Chen IM, Johansen AZ, Nordestgaard BG, Bojesen SE, Johansen JS. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. Cancers (Basel) 2021;13:4599. [PMID: 34572824 DOI: 10.3390/cancers13184599] [Reference Citation Analysis]
505 Uesato Y, Sasahira N, Ozaka M, Sasaki T, Takatsuki M, Zembutsu H. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis. PLoS One 2020;15:e0235623. [PMID: 32614932 DOI: 10.1371/journal.pone.0235623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
506 Görgülü K, Diakopoulos KN, Kaya-Aksoy E, Ciecielski KJ, Ai J, Lesina M, Algül H. The Role of Autophagy in Pancreatic Cancer: From Bench to the Dark Bedside. Cells 2020;9:E1063. [PMID: 32344698 DOI: 10.3390/cells9041063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
507 MacCurtain BM, Quirke NP, Thorpe SD, Gallagher TK. Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis. J Clin Med 2021;10:2711. [PMID: 34205335 DOI: 10.3390/jcm10122711] [Reference Citation Analysis]
508 Sato T, Shibata W, Hikiba Y, Kaneta Y, Suzuki N, Ihara S, Ishii Y, Sue S, Kameta E, Sugimori M, Yamada H, Kaneko H, Sasaki T, Ishii T, Tamura T, Kondo M, Maeda S. c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice. Cancer Sci. 2017;108:2156-2165. [PMID: 28837246 DOI: 10.1111/cas.13382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
509 Ge J, Li L, Ma Z, Jiang B, Yuan C, Wang H, Peng Y, Xiu D. A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration. Gland Surg 2021;10:279-89. [PMID: 33633984 DOI: 10.21037/gs-20-605] [Reference Citation Analysis]
510 Azizi M, Dianat-Moghadam H, Salehi R, Farshbaf M, Iyengar D, Sau S, Iyer AK, Valizadeh H, Mehrmohammadi M, Hamblin MR. Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications. Adv Funct Mater 2020;30:1910402. [PMID: 34093104 DOI: 10.1002/adfm.201910402] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
511 Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019;9:1280-7. [PMID: 30867830 DOI: 10.7150/thno.29247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
512 Zhang M, Hu X, Kang Y, Xu W, Yang X. Association between fasting blood glucose levels at admission and overall survival of patients with pancreatic cancer. BMC Cancer 2021;21:131. [PMID: 33549043 DOI: 10.1186/s12885-021-07859-9] [Reference Citation Analysis]
513 Kirkegård J, Gaber C, Lund JL, Hinton SP, Ladekarl M, Heide-Jørgensen U, Cronin-Fenton D, Mortensen FV. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Cancer Epidemiol 2020;64:101647. [PMID: 31811984 DOI: 10.1016/j.canep.2019.101647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
514 Di Carlo C, Brandi J, Cecconi D. Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma. World J Stem Cells 2018; 10(11): 172-182 [PMID: 30631392 DOI: 10.4252/wjsc.v10.i11.172] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
515 Patki M, Saraswat A, Bhutkar S, Dukhande V, Patel K. In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. Exp Cell Res 2021;405:112660. [PMID: 34048785 DOI: 10.1016/j.yexcr.2021.112660] [Reference Citation Analysis]
516 Chen H, Bian A, Yang LF, Yin X, Wang J, Ti C, Miao Y, Peng S, Xu S, Liu M, Qiu WW, Yi Z. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Oncogene 2021;40:1440-57. [PMID: 33420372 DOI: 10.1038/s41388-020-01626-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
517 Yu L, Teoh ST, Ensink E, Ogrodzinski MP, Yang C, Vazquez AI, Lunt SY. Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells. Cancer Metab 2019;7:13. [PMID: 31893043 DOI: 10.1186/s40170-019-0205-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
518 de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. J Gastrointest Surg 2018;22:214-25. [PMID: 29235000 DOI: 10.1007/s11605-017-3541-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
519 Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore) 2017;96:e5702. [PMID: 28072706 DOI: 10.1097/MD.0000000000005702] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
520 Wakiya T, Ishido K, Yoshizawa T, Kanda T, Hakamada K. Roles of the nervous system in pancreatic cancer. Ann Gastroenterol Surg 2021;5:623-33. [PMID: 34585047 DOI: 10.1002/ags3.12459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Werle SD, Schwab JD, Tatura M, Kirchhoff S, Szekely R, Diels R, Ikonomi N, Sipos B, Sperveslage J, Gress TM, Buchholz M, Kestler HA. Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer. Cancers (Basel) 2021;13:725. [PMID: 33578795 DOI: 10.3390/cancers13040725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Xu Z, Pang TCY, Liu AC, Pothula SP, Mekapogu AR, Perera CJ, Murakami T, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br J Cancer 2020;122:1486-95. [PMID: 32203220 DOI: 10.1038/s41416-020-0782-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
523 McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology. 2019;157:823-837. [PMID: 31078621 DOI: 10.1053/j.gastro.2019.05.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 16.7] [Reference Citation Analysis]
524 Siret C, Dobric A, Martirosyan A, Terciolo C, Germain S, Bonier R, Dirami T, Dusetti N, Tomasini R, Rubis M, Garcia S, Iovanna J, Lombardo D, Rigot V, André F. Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma. Br J Cancer 2018;118:546-57. [PMID: 29161242 DOI: 10.1038/bjc.2017.411] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
525 Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics 2020;10:5802-14. [PMID: 32483420 DOI: 10.7150/thno.44772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
526 Liu AD, Zhou J, Bi XY, Hou GQ, Li SS, Chen Q, Xu H, Cao X. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. Clin Transl Med 2021;11:e337. [PMID: 33783993 DOI: 10.1002/ctm2.337] [Reference Citation Analysis]
527 Pei Y, Chen L, Huang Y, Wang J, Feng J, Xu M, Chen Y, Song Q, Jiang G, Gu X, Zhang Q, Gao X, Chen J. Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Small 2019;15:1900631. [DOI: 10.1002/smll.201900631] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
528 Wei R, Hackman RM, Wang Y, Mackenzie GG. Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. Cancers (Basel) 2019;11:E1496. [PMID: 31590367 DOI: 10.3390/cancers11101496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
529 Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol 2019;30:1959-68. [PMID: 31562758 DOI: 10.1093/annonc/mdz406] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
530 Kokkinos J, Ignacio RMC, Sharbeen G, Boyer C, Gonzales-Aloy E, Goldstein D, Australian Pancreatic Cancer Genome Initiative Apgi, McCarroll JA, Phillips PA. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials 2020;240:119742. [PMID: 32088410 DOI: 10.1016/j.biomaterials.2019.119742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
531 Quillien L, Top S, Kappler-Gratias S, Redouté A, Dusetti N, Quentin-Froignant C, Lulka H, Camus-Bouclainville C, Buscail L, Gallardo F, Bertagnoli S, Cordelier P. A Novel Imaging Approach for Single-Cell Real-Time Analysis of Oncolytic Virus Replication and Efficacy in Cancer Cells. Hum Gene Ther 2021;32:166-77. [PMID: 33504260 DOI: 10.1089/hum.2020.294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
532 Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 2017;5. [PMID: 29156578 DOI: 10.3390/biomedicines5040065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
533 Boas FE, Nurili F, Bendet A, Cheleuitte-Nieves C, Basturk O, Askan G, Michel AO, Monette S, Ziv E, Sofocleous CT, Maxwell AWP, Schook LB, Solomon SB, Kelsen DP, Scherz A, Yarmohammadi H. Induction and characterization of pancreatic cancer in a transgenic pig model. PLoS One 2020;15:e0239391. [PMID: 32956389 DOI: 10.1371/journal.pone.0239391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
534 Fitts CA, Ji N, Li Y, Tan C. Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery. Adv Healthcare Mater 2019;8:1801268. [DOI: 10.1002/adhm.201801268] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
535 Seicean A, Samarghitan A, Bolboacă SD, Pojoga C, Rusu I, Rusu D, Sparchez Z, Gheorghiu M, Al Hajjar N, Seicean R. Contrast-enhanced harmonic versus standard endoscopic ultrasound-guided fine-needle aspiration in solid pancreatic lesions: a single-center prospective randomized trial. Endoscopy 2020;52:1084-90. [DOI: 10.1055/a-1193-4954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
536 Liu Q, Zhang R, Michalski CW, Liu B, Liao Q, Kleeff J. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Sci Rep 2020;10:4444. [PMID: 32157155 DOI: 10.1038/s41598-020-61487-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
537 Zhou L, Wang J, Zhang XX, Lyu SC, Pan LC, Du GS, Lang R, He Q. Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study. Front Oncol 2021;11:682928. [PMID: 34604028 DOI: 10.3389/fonc.2021.682928] [Reference Citation Analysis]
538 Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C. 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2019;11:E1531. [PMID: 31658755 DOI: 10.3390/cancers11101531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
539 Qu D, Weygant N, Yao J, Chandrakesan P, Berry WL, May R, Pitts K, Husain S, Lightfoot S, Li M, Wang TC, An G, Clendenin C, Stanger BZ, Houchen CW. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. J Oncol 2019;2019:6402925. [PMID: 31467540 DOI: 10.1155/2019/6402925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
540 Shen YJ, Cao J, Sun F, Cai XL, Li MM, Zheng NN, Qu CY, Zhang Y, Shen F, Zhou M, Chen YW, Xu LM. Effect of photodynamic therapy with (17R,18R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt on pancreatic cancer cells in vitro and in vivoWorld J Gastroenterol 2018; 24(46): 5246-5258 [PMID: 30581273 DOI: 10.3748/wjg.v24.i46.5246] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
541 Barlass U, Deshmukh A, Beck T, Bishehsari F. Opioid use as a potential risk factor for pancreatic cancer in the United States: An analysis of state and national level databases. PLoS One 2021;16:e0244285. [PMID: 33406096 DOI: 10.1371/journal.pone.0244285] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
543 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 24.7] [Reference Citation Analysis]
544 Hintzen KFH, Grote J, Wintjens AGWE, Lubbers T, Eussen MMM, van Schooten FJ, Bouvy ND, Peeters A. Breath analysis for the detection of digestive tract malignancies: systematic review. BJS Open 2021;5:zrab013. [PMID: 33855362 DOI: 10.1093/bjsopen/zrab013] [Reference Citation Analysis]
545 Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel) 2021;13:799. [PMID: 33672917 DOI: 10.3390/cancers13040799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
546 Li Y, Su Z, Wei B, Qin M, Liang Z. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis. Math Biosci Eng 2021;18:5921-42. [PMID: 34517516 DOI: 10.3934/mbe.2021296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Zhu L, Staley C, Kooby D, El-Rays B, Mao H, Yang L. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Lett 2017;388:139-48. [PMID: 27916607 DOI: 10.1016/j.canlet.2016.11.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
548 Onodera T, Momose I, Adachi H, Yamazaki Y, Sawa R, Ohba SI, Kawada M. Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition. J Biol Chem 2020;295:16678-90. [PMID: 32978257 DOI: 10.1074/jbc.RA120.013893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Xie ZB, Yao L, Jin C, Zhang YF, Fu DL. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients. Eur J Surg Oncol 2019;45:207-12. [PMID: 30389300 DOI: 10.1016/j.ejso.2018.09.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
550 Hu S, Jin Y, Liu Y, Ljungman M, Neamati N. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. Eur J Med Chem 2018;158:884-95. [PMID: 30253345 DOI: 10.1016/j.ejmech.2018.09.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
551 Guerrero PE, Duran A, Ortiz MR, Castro E, Garcia-Velasco A, Llop E, Peracaula R. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. J Proteomics 2021;231:104004. [PMID: 33038510 DOI: 10.1016/j.jprot.2020.104004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
552 Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology. 2019;156:2024-2040. [PMID: 30721664 DOI: 10.1053/j.gastro.2019.01.259] [Cited by in Crossref: 142] [Cited by in F6Publishing: 130] [Article Influence: 47.3] [Reference Citation Analysis]
553 Choi MH, Yoon SB, Song M, Lee IS, Hong TH, Lee MA, Jung ES. Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. PLoS One 2020;15:e0240318. [PMID: 33027288 DOI: 10.1371/journal.pone.0240318] [Reference Citation Analysis]
554 Teng T, Lin R, Lin Z, Ke K, Lin X, Pan M, Zhang D, Huang H. Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode. Biomater Sci 2020;8:3278-85. [PMID: 32355947 DOI: 10.1039/d0bm00549e] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Chou CY, Chang CT, Chen CJ. Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry. Rapid Commun Mass Spectrom 2020;34 Suppl 1:e8580. [PMID: 31502717 DOI: 10.1002/rcm.8580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
556 Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis 2018;9:445. [PMID: 29670075 DOI: 10.1038/s41419-018-0478-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
557 Regel I, Mayerle J, Mahajan UM. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2020;12:E1024. [PMID: 32326341 DOI: 10.3390/cancers12041024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
558 Naqvi AAT, Hasan GM, Hassan MI. Investigating the role of transcription factors of pancreas development in pancreatic cancer. Pancreatology 2018;18:184-90. [DOI: 10.1016/j.pan.2017.12.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
559 Wang J, Xiang J, Li X. Construction of a Competitive Endogenous RNA Network for Pancreatic Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis and a Prognosis Model. Front Bioeng Biotechnol 2020;8:515. [PMID: 32548103 DOI: 10.3389/fbioe.2020.00515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
560 Jin L, Zhu C, Qin X. Expression profile of tRNA-derived fragments in pancreatic cancer. Oncol Lett 2019;18:3104-14. [PMID: 31452788 DOI: 10.3892/ol.2019.10601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
561 Cheng Q, Ouyang X, Zhang R, Zhu L, Song X. Senescence-associated genes and non-coding RNAs function in pancreatic cancer progression. RNA Biol 2020;17:1693-706. [PMID: 31997706 DOI: 10.1080/15476286.2020.1719752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
562 Traub B, Sun L, Ma Y, Xu P, Lemke J, Paschke S, Henne-Bruns D, Knippschild U, Kornmann M. Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Int J Mol Sci 2017;18:E716. [PMID: 28350325 DOI: 10.3390/ijms18040716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
563 Amrutkar M, Vethe NT, Verbeke CS, Aasrum M, Finstadsveen AV, Sántha P, Gladhaug IP. Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Cancers (Basel) 2020;12:E3628. [PMID: 33287390 DOI: 10.3390/cancers12123628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
564 Wang P, Zhang C, Li W, Zhai B, Jiang X, Reddy S, Jiang H, Sun X. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Cell Commun Signal 2020;18:34. [PMID: 32122386 DOI: 10.1186/s12964-020-0522-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
565 Kandhari K, Paudel S, Raina K, Agarwal C, Kant R, Wempe MF, O'Bryant C, Agarwal R. Comparative Pre-clinical Efficacy of Chinese and Indian Cultivars of Bitter Melon (Momordica charantia) against Pancreatic Cancer. J Cancer Prev 2021;26:266-76. [PMID: 35047453 DOI: 10.15430/JCP.2021.26.4.266] [Reference Citation Analysis]
566 Gablo N, Trachtova K, Prochazka V, Hlavsa J, Grolich T, Kiss I, Srovnal J, Rehulkova A, Lovecek M, Skalicky P, Berindan-Neagoe I, Kala Z, Slaby O. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. J Clin Med 2020;9:E2440. [PMID: 32751582 DOI: 10.3390/jcm9082440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
567 Shen Y, Li M, Sun F, Zhang Y, Qu C, Zhou M, Shen F, Xu L. Low-dose photodynamic therapy-induced increase in the metastatic potential of pancreatic tumor cells and its blockade by simvastatin. Journal of Photochemistry and Photobiology B: Biology 2020;207:111889. [DOI: 10.1016/j.jphotobiol.2020.111889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
568 Li J, Kang R, Tang D. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Cancer Commun (Lond) 2021;41:642-60. [PMID: 34264020 DOI: 10.1002/cac2.12188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
569 Kleeff J, Costello E, Jackson R, Halloran C, Greenhalf W, Ghaneh P, Lamb RF, Lerch MM, Mayerle J, Palmer D, Cox T, Rawcliffe CL, Strobel O, Büchler MW, Neoptolemos JP. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 2016;115:887-94. [PMID: 27584663 DOI: 10.1038/bjc.2016.277] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
570 Delayre T, Guilbaud T, Resseguier N, Mamessier E, Rubis M, Moutardier V, Fara R, Berdah SV, Garcia S, Birnbaum DJ. Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection. Br J Surg 2020;107:720-33. [PMID: 31960955 DOI: 10.1002/bjs.11434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
571 Lombardo D, Silvy F, Crenon I, Martinez E, Collignon A, Beraud E, Mas E. Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies? Oncotarget 2018;9:12513-33. [PMID: 29552330 DOI: 10.18632/oncotarget.23619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
572 Bijou I, Wang J. Evolving trends in pancreatic cancer therapeutic development. Ann Pancreat Cancer 2019;2:17. [PMID: 33089149 DOI: 10.21037/apc.2019.09.01] [Reference Citation Analysis]
573 Chung MJ, Park SW, Kim SH, Cho CM, Choi JH, Choi EK, Lee TH, Cho E, Lee JK, Song TJ, Lee JM, Son JH, Park JS, Oh CH, Park DA, Byeon JS, Lee ST, Kim HG, Chun HJ, Choi HS, Park CG, Cho JY. Clinical and Technical Guideline for Endoscopic Ultrasound (EUS)-Guided Tissue Acquisition of Pancreatic Solid Tumor: Korean Society of Gastrointestinal Endoscopy (KSGE). Clin Endosc 2021;54:161-81. [PMID: 33761231 DOI: 10.5946/ce.2021.069] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
574 Igarashi T, Araki K, Yokobori T, Altan B, Yamanaka T, Ishii N, Tsukagoshi M, Watanabe A, Kubo N, Handa T, Hosouchi Y, Nishiyama M, Oyama T, Shirabe K, Kuwano H. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Oncotarget 2017;8:12290-300. [PMID: 28103577 DOI: 10.18632/oncotarget.14703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
575 Wei K, Hackert T. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:1971. [PMID: 33923884 DOI: 10.3390/cancers13081971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
576 Kobayashi M, Fujita A, Ogawa T, Tanisaka Y, Mizuide M, Kondo N, Imaizumi Y, Hirotsu T, Ryozawa S. Caenorhabditis elegans as a Diagnostic Aid for Pancreatic Cancer. Pancreas 2021;50:673-8. [PMID: 34016888 DOI: 10.1097/MPA.0000000000001814] [Reference Citation Analysis]
577 Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Vandetanib plus gemcitabine vs placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncol. 2017;18:486-499. [PMID: 28259610 DOI: 10.1016/s1470-2045(17)30084-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
578 Mohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J, Cros J, Nicolle R, Iovanna J, Dusetti N, Mas E. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 2021;71:103541. [PMID: 34425307 DOI: 10.1016/j.ebiom.2021.103541] [Reference Citation Analysis]
579 Kozawa K, Sekai M, Ohba K, Ito S, Sako H, Maruyama T, Kakeno M, Shirai T, Kuromiya K, Kamasaki T, Kohashi K, Tanaka S, Ishikawa S, Sato N, Asano S, Suzuki H, Tanimura N, Mukai Y, Gotoh N, Tanino M, Tanaka S, Natsuga K, Soga T, Nakamura T, Yabuta Y, Saitou M, Ito T, Matsuura K, Tsunoda M, Kikumori T, Iida T, Mizutani Y, Miyai Y, Kaibuchi K, Enomoto A, Fujita Y. The CD44/COL17A1 pathway promotes the formation of multilayered, transformed epithelia. Curr Biol 2021;31:3086-3097.e7. [PMID: 34087104 DOI: 10.1016/j.cub.2021.04.078] [Reference Citation Analysis]
580 Bergquist JR, Thiels CA, Shubert CR, Ivanics T, Habermann EB, Vege SS, Grotz TE, Cleary SP, Smoot RL, Kendrick ML, Nagorney DM, Truty MJ. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Cancer Med 2021. [PMID: 34289264 DOI: 10.1002/cam4.4144] [Reference Citation Analysis]
581 Vanderwerff BR, Church KJ, Kawas LH, Harding JW. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma. Cytokine 2019;123:154762. [DOI: 10.1016/j.cyto.2019.154762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
582 Kanda T, Wakiya T, Ishido K, Kimura N, Nagase H, Kubota S, Fujita H, Hagiwara Y, Hakamada K. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching Analysis. Pancreas 2021;50:1314-25. [PMID: 34860818 DOI: 10.1097/MPA.0000000000001913] [Reference Citation Analysis]
583 Ge Y, Liu H, Zhang Y, Liu J, Yan R, Xiao Z, Fan X, Huang X, An G. Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Transl Oncol 2022;17:101317. [PMID: 34998236 DOI: 10.1016/j.tranon.2021.101317] [Reference Citation Analysis]
584 Waldenmaier M, Seibold T, Seufferlein T, Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel) 2021;13:4844. [PMID: 34638330 DOI: 10.3390/cancers13194844] [Reference Citation Analysis]
585 Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC Palliat Care 2020;19:103. [PMID: 32650765 DOI: 10.1186/s12904-020-00610-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
586 Kim MJ, Chang H, Nam G, Ko Y, Kim SH, Roberts TM, Ryu JH. RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics 2021;13:1638. [PMID: 34683931 DOI: 10.3390/pharmaceutics13101638] [Reference Citation Analysis]
587 de Koning W, Latifi D, Li Y, van Eijck CHJ, Stubbs AP, Mustafa DAM. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes. Front Immunol 2021;12:649061. [PMID: 33986743 DOI: 10.3389/fimmu.2021.649061] [Reference Citation Analysis]
588 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
589 Alcalá S, Mayoral-Varo V, Ruiz-Cañas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B Jr. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int J Mol Sci 2020;21:E7437. [PMID: 33050159 DOI: 10.3390/ijms21207437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
590 Thomas D, Radhakrishnan P. Pancreatic Stellate Cells: The Key Orchestrator of The Pancreatic Tumor Microenvironment. Adv Exp Med Biol 2020;1234:57-70. [PMID: 32040855 DOI: 10.1007/978-3-030-37184-5_5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
591 Minici C, Rigamonti E, Lanzillotta M, Monno A, Rovati L, Maehara T, Kaneko N, Deshpande V, Protti MP, De Monte L, Scielzo C, Crippa S, Arcidiacono PG, Dugnani E, Piemonti L, Falconi M, Pillai S, Manfredi AA, Della-Torre E. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Oncoimmunology 2020;9:1794359. [PMID: 32923157 DOI: 10.1080/2162402X.2020.1794359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
592 Valle S, Martin-Hijano L, Alcalá S, Alonso-Nocelo M, Sainz B Jr. The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. Cancers (Basel) 2018;10:E33. [PMID: 29373514 DOI: 10.3390/cancers10020033] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
593 Kawalerski RR, Leach SD, Escobar-Hoyos LF. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Oncotarget 2021;12:525-33. [PMID: 33796221 DOI: 10.18632/oncotarget.27901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
594 Balachandran VP, Beatty GL, Dougan SK. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology 2019;156:2056-72. [PMID: 30660727 DOI: 10.1053/j.gastro.2018.12.038] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 31.7] [Reference Citation Analysis]
595 Guo JA, Hoffman HI, Weekes CD, Zheng L, Ting DT, Hwang WL. Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clin Cancer Res 2021;27:3825-33. [PMID: 33653818 DOI: 10.1158/1078-0432.CCR-20-4712] [Reference Citation Analysis]
596 Huang L, Desai R, Conrad DN, Leite NC, Akshinthala D, Lim CM, Gonzalez R, Muthuswamy LB, Gartner Z, Muthuswamy SK. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell 2021;28:1090-1104.e6. [PMID: 33915081 DOI: 10.1016/j.stem.2021.03.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
597 Dickerson LD, Farooq A, Bano F, Kleeff J, Baron R, Raraty M, Ghaneh P, Sutton R, Whelan P, Campbell F, Healey P, Neoptolemos JP, Yip VS. Differentiation of Autoimmune Pancreatitis from Pancreatic Cancer Remains Challenging. World J Surg 2019;43:1604-11. [PMID: 30815742 DOI: 10.1007/s00268-019-04928-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
598 Tan W, Duong MT, Zuo C, Qin Y, Zhang Y, Guo Y, Hong Y, Zheng JH, Min JJ. Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Mol Ther 2021:S1525-0016(21)00417-2. [PMID: 34400328 DOI: 10.1016/j.ymthe.2021.08.023] [Reference Citation Analysis]
599 Thompson B, Philcox S, Devereaux B, Metz A, Croagh D, Windsor J, Davaris A, Gupta S, Barlow J, Rhee J, Tagkalidis P, Zimet A, Sharma A, Manocha R, Neale RE. A decision support tool for the detection of pancreatic cancer in general practice: A modified Delphi consensus. Pancreatology 2021:S1424-3903(21)00530-5. [PMID: 34483054 DOI: 10.1016/j.pan.2021.08.007] [Reference Citation Analysis]
600 Wang C, Wei Y, Wang G, Zhou Y, Zhang J, Xu K. Heparanase potentiates the invasion and migration of pancreatic cancer cells via epithelial‑to‑mesenchymal transition through the Wnt/β‑catenin pathway. Oncol Rep 2020;44:711-21. [PMID: 32627022 DOI: 10.3892/or.2020.7641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
601 Dong X, Ma Y, Zhao X, Tian X, Sun Y, Yang Y, Zhao X. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer patients. Ann Transl Med 2020;8:676. [PMID: 32617296 DOI: 10.21037/atm-20-782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
602 Li Z, Yu X, Werner J, Bazhin AV, D'Haese JG. The role of interleukin-18 in pancreatitis and pancreatic cancer. Cytokine Growth Factor Rev 2019;50:1-12. [PMID: 31753718 DOI: 10.1016/j.cytogfr.2019.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
603 Kabacaoglu D, Ruess DA, Ai J, Algül H. NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. Cancers (Basel) 2019;11:E937. [PMID: 31277415 DOI: 10.3390/cancers11070937] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
604 Yang Y, Tian W, Yang L, Zhang Q, Zhu M, Liu Y, Li J, Yang L, Liu J, Shen Y, Qi Z. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B. J Cancer Res Clin Oncol 2021;147:93-103. [PMID: 32897433 DOI: 10.1007/s00432-020-03384-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
605 Hruban RH, Gaida MM, Thompson E, Hong SM, Noë M, Brosens LA, Jongepier M, Offerhaus GJA, Wood LD. Why is pancreatic cancer so deadly? The pathologist's view. J Pathol 2019;248:131-41. [PMID: 30838636 DOI: 10.1002/path.5260] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
606 Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, Ghavidel AA, Teymouri A, Roshanzamiri S, Farhadi S, Ghanbarian H. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng 2021. [PMID: 34170520 DOI: 10.1002/bit.27869] [Reference Citation Analysis]
607 Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut 2020;69:1472-82. [PMID: 32001555 DOI: 10.1136/gutjnl-2018-317856] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
608 Chen D, Zhu X, Tao W, Kong Y, Huag Y, Zhang Y, Liu R, Jiang L, Tang Y, Yu H, Hao Q, Yang X, Zou H, Chen J, Lu Y, Zhang H, Li W. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Journal of Controlled Release 2020;324:545-59. [DOI: 10.1016/j.jconrel.2020.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
609 Beshay PE, Cortes-medina MG, Menyhert MM, Song JW. The Biophysics of Cancer: Emerging Insights from Micro‐ and Nanoscale Tools. Advanced NanoBiomed Research 2022;2:2100056. [DOI: 10.1002/anbr.202100056] [Reference Citation Analysis]
610 Wang X, Zhang J, Wu H, Li Y, Conti PS, Chen K. PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide. Amino Acids 2018;50:897-907. [PMID: 29691700 DOI: 10.1007/s00726-018-2566-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
611 Principe DR, Korc M, Kamath SD, Munshi HG, Rana A. Trials and tribulations of pancreatic cancer immunotherapy. Cancer Lett 2021;504:1-14. [PMID: 33549709 DOI: 10.1016/j.canlet.2021.01.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
612 Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Seimiya T, Sekiba K, Ohno M, Iwata T, Ishibashi R, Otsuka M, Koike K. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther 2021. [PMID: 33833413 DOI: 10.1038/s41417-021-00326-4] [Reference Citation Analysis]
613 Mollinedo F, Gajate C. Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response. Ann Transl Med 2019;7:S153. [PMID: 31576360 DOI: 10.21037/atm.2019.06.40] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
614 Ielpo B. The issue of how predict survival of patients affected by locally advanced pancreatic cancer. Ann Transl Med 2018;6:S128. [PMID: 30740449 DOI: 10.21037/atm.2018.12.41] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
615 Tozzi M, Sørensen CE, Magni L, Christensen NM, Bouazzi R, Buch CM, Stefanini M, Duranti C, Arcangeli A, Novak I. Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2020;12:E640. [PMID: 32164284 DOI: 10.3390/cancers12030640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
616 Ávila-López PA, Guerrero G, Nuñez-Martínez HN, Peralta-Alvarez CA, Hernández-Montes G, Álvarez-Hilario LG, Herrera-Goepfert R, Albores-Saavedra J, Villegas-Sepúlveda N, Cedillo-Barrón L, Montes-Gómez AE, Vargas M, Schnoor M, Recillas-Targa F, Hernández-Rivas R. H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma. Oncogene 2021;40:2065-80. [PMID: 33627784 DOI: 10.1038/s41388-021-01664-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
617 Zhang X, Hong K, Sun Q, Zhu Y, Du J. Bioreducible, arginine-rich polydisulfide-based siRNA nanocomplexes with excellent tumor penetration for efficient gene silencing. Biomater Sci 2021;9:5275-92. [PMID: 34180478 DOI: 10.1039/d1bm00643f] [Reference Citation Analysis]
618 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
619 Kirkegård J, Al-Saiddi M, Bratlie SO, Coolsen M, de Haas RJ, den Dulk M, Fristrup C, Greve OJ, Harrison E, Koutouzi G, Miclea RL, Mortensen MB, Nijkamp MW, Persson J, Robertson FP, Slangen JJG, Søreide JA, Wigmore SJ, Mortensen FV. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. J Surg Oncol 2021. [PMID: 34490905 DOI: 10.1002/jso.26670] [Reference Citation Analysis]
620 Qi B, Liu H, Zhou Q, Ji L, Shi X, Wei Y, Gu Y, Mizushima A, Xia S. An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma. Aging (Albany NY) 2021;13:18806-26. [PMID: 34285140 DOI: 10.18632/aging.203323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
621 Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Ther Adv Med Oncol 2021;13:17588359211045860. [PMID: 34691244 DOI: 10.1177/17588359211045860] [Reference Citation Analysis]
622 Fujita Y, Matsuda S, Sasaki Y, Masugi Y, Kitago M, Yagi H, Abe Y, Shinoda M, Tokino T, Sakamoto M, Kitagawa Y. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis. Cancer Sci. 2020;111:739-748. [PMID: 31799787 DOI: 10.1111/cas.14268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
623 Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rümmele P, Knösel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. EBioMedicine 2019;40:394-405. [PMID: 30709769 DOI: 10.1016/j.ebiom.2019.01.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
624 Aguilar-Valdés A, Noriega LG, Tovar AR, Ibarra-Sánchez MJ, Sosa-Hernández VA, Maravillas-Montero JL, Martínez-Aguilar J. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition. Biochem Biophys Res Commun 2021;552:23-9. [PMID: 33740661 DOI: 10.1016/j.bbrc.2021.03.018] [Reference Citation Analysis]
625 Henze J, Tacke F, Hardt O, Alves F, Al Rawashdeh W. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1389. [PMID: 32481570 DOI: 10.3390/cancers12061389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
626 Truong LH, Pauklin S. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers (Basel) 2021;13:5028. [PMID: 34638513 DOI: 10.3390/cancers13195028] [Reference Citation Analysis]
627 Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res 2018;78:5656-67. [PMID: 30217928 DOI: 10.1158/0008-5472.CAN-17-3939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
628 Li C, Zeng X, Yu H, Gu Y, Zhang W. Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods. World J Surg Oncol 2018;16:223. [PMID: 30428899 DOI: 10.1186/s12957-018-1519-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
629 Peng C, Wang J, Gao W, Huang L, Liu Y, Li X, Li Z, Yu X. Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer. Int J Med Sci 2021;18:660-71. [PMID: 33437201 DOI: 10.7150/ijms.52706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Rossi Sebastiano M, Pozzato C, Saliakoura M, Yang Z, Peng RW, Galiè M, Oberson K, Simon HU, Karamitopoulou E, Konstantinidou G. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Sci Adv 2020;6:eabb9200. [PMID: 33127675 DOI: 10.1126/sciadv.abb9200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
631 You MS, Ryu JK, Huh G, Chun JW, Paik WH, Lee SH, Kim YT. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. World J Clin Oncol 2020; 11(9): 747-760 [PMID: 33033696 DOI: 10.5306/wjco.v11.i9.747] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
632 Chen W, Zhou Y, Zhi X, Ma T, Liu H, Chen BW, Zheng X, Xie S, Zhao B, Feng X, Dang X, Liang T. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Biomaterials 2019;192:590-600. [PMID: 30553134 DOI: 10.1016/j.biomaterials.2018.11.035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
633 Ruckert MT, de Andrade PV, Santos VS, Silveira VS. Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma. Cell Mol Life Sci 2019;76:2571-92. [PMID: 30982078 DOI: 10.1007/s00018-019-03095-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
634 Brown WS, McDonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, Li J, Renouf DJ, Stanger BZ, Dedhar S. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Cell Rep Med 2020;1:100131. [PMID: 33294856 DOI: 10.1016/j.xcrm.2020.100131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
635 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
636 Chen K, Zhou Y, Jin W, Zhu Q, Lu C, Niu N, Wang Y, Mou Y, Chen Z. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Surg Endosc. 2020;34:1948-1958. [PMID: 31317331 DOI: 10.1007/s00464-019-06968-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
637 Fahr L, Sunami Y, Maeritz N, Steiger K, Grünewald TGP, Gericke M, Kong B, Raulefs S, Mayerle J, Michalski CW, Regel I, Kleeff J. Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis. Pancreatology 2020;20:1673-81. [PMID: 33051146 DOI: 10.1016/j.pan.2020.10.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
638 He S, Dong G, Li Y, Wu S, Wang W, Sheng C. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angew Chem Int Ed Engl 2020;59:3028-32. [PMID: 31943585 DOI: 10.1002/anie.201915896] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
639 Korc M. RelA: a tale of a stitch in time. J Clin Invest 2016;126:2799-801. [PMID: 27454293 DOI: 10.1172/JCI89156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
640 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol 2021;9:743908. [PMID: 34805152 DOI: 10.3389/fcell.2021.743908] [Reference Citation Analysis]
641 Nakamura K, Sho M, Akahori T, Nishiwada S, Kunishige T, Nakagawa K, Nagai M, Takagi T, Terai T, Ikeda N. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Pancreatology 2021;21:573-80. [PMID: 33541781 DOI: 10.1016/j.pan.2021.01.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Yu Y, Zheng P, Chen Y, Wang B, Paul ME, Tao P, Wang D, Li H, Gu B, Gao L, Wang D, Chen H. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Asia Pac J Clin Oncol 2020. [PMID: 33164329 DOI: 10.1111/ajco.13504] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita YI, Reber HA, Baba H. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Pancreas 2017;46:1083-90. [PMID: 28902776 DOI: 10.1097/MPA.0000000000000897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
644 Zhang J, Lan Z, Qiu G, Ren H, Zhao Y, Gu Z, Li Z, Feng L, He J, Wang C. Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin. BMC Cancer 2020;20:1065. [PMID: 33148205 DOI: 10.1186/s12885-020-07556-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
645 Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, Kaifi JT, Miao Y, Li M, Jiang K, Li G. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett 2019;454:204-14. [PMID: 31004701 DOI: 10.1016/j.canlet.2019.04.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
646 Brocco D, Florio R, De Lellis L, Veschi S, Grassadonia A, Tinari N, Cama A. The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. Cancers (Basel) 2020;12:E1849. [PMID: 32659999 DOI: 10.3390/cancers12071849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
647 Rath N, Munro J, Cutiongco MF, Jagiełło A, Gadegaard N, McGarry L, Unbekandt M, Michalopoulou E, Kamphorst JJ, Sumpton D, Mackay G, Vennin C, Pajic M, Timpson P, Olson MF. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Cancer Res 2018;78:3321-36. [PMID: 29669760 DOI: 10.1158/0008-5472.CAN-17-1339] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
648 Alicandro G, Tavani A, La Vecchia C. Coffee and cancer risk: a summary overview. Eur J Cancer Prev 2017;26:424-32. [PMID: 28288025 DOI: 10.1097/CEJ.0000000000000341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
649 Sunami Y, Rebelo A, Kleeff J. Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2017;10:E3. [PMID: 29295482 DOI: 10.3390/cancers10010003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
650 Baekelandt BMG, Fagerland MW, Hjermstad MJ, Heiberg T, Labori KJ, Buanes TA. Survival, Complications and Patient Reported Outcomes after Pancreatic Surgery. HPB (Oxford). 2018;. [PMID: 30120002 DOI: 10.1016/j.hpb.2018.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
651 Boraschi P, Tarantini G, Donati F, Scalise P, Cervelli R, Caramella D. Side-branch intraductal papillary mucinous neoplasms of the pancreas: outcome of MR imaging surveillance over a 10 years follow-up. Eur J Radiol Open 2020;7:100250. [PMID: 32884981 DOI: 10.1016/j.ejro.2020.100250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
652 Ronellenfitsch U, Michalski CW, Michl P, Krug S, Ukkat J, Kleeff J. Pre-operative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer (PREVADER): Clinical Feasibility Trial. Front Med (Lausanne) 2021;8:588375. [PMID: 34109185 DOI: 10.3389/fmed.2021.588375] [Reference Citation Analysis]
653 Schäfer D, Tomiuk S, Küster LN, Rawashdeh WA, Henze J, Tischler-Höhle G, Agorku DJ, Brauner J, Linnartz C, Lock D, Kaiser A, Herbel C, Eckardt D, Lamorte M, Lenhard D, Schüler J, Ströbel P, Missbach-Guentner J, Pinkert-Leetsch D, Alves F, Bosio A, Hardt O. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 2021;12:1453. [PMID: 33674603 DOI: 10.1038/s41467-021-21774-4] [Reference Citation Analysis]
654 Enane FO, Saunthararajah Y, Korc M. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018;9:912. [PMID: 30190481 DOI: 10.1038/s41419-018-0919-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
655 Kretz AL, von Karstedt S, Hillenbrand A, Henne-Bruns D, Knippschild U, Trauzold A, Lemke J. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers (Basel) 2018;10:E77. [PMID: 29562636 DOI: 10.3390/cancers10030077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
656 Carioli G, La Vecchia C, Bertuccio P, Rodriguez T, Levi F, Boffetta P, Negri E, Malvezzi M. Cancer mortality predictions for 2017 in Latin America. Annals of Oncology 2017;28:2286-97. [DOI: 10.1093/annonc/mdx301] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
657 Barańska E, Wiecheć-Cudak O, Rak M, Bienia A, Mrozek-Wilczkiewicz A, Krzykawska-Serda M, Serda M. Interactions of a Water-Soluble Glycofullerene with Glucose Transporter 1. Analysis of the Cellular Effects on a Pancreatic Tumor Model. Nanomaterials (Basel) 2021;11:513. [PMID: 33670509 DOI: 10.3390/nano11020513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
658 Zhao X, Zhang Q, Wang Y, Li S, Yu X, Wang B, Wang X. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann Transl Med 2021;9:1084. [PMID: 34422996 DOI: 10.21037/atm-21-2630] [Reference Citation Analysis]
659 Liu J, Luo X, Guo R, Jing W, Lu H. Cell Metabolomics Reveals Berberine-Inhibited Pancreatic Cancer Cell Viability and Metastasis by Regulating Citrate Metabolism. J Proteome Res 2020;19:3825-36. [DOI: 10.1021/acs.jproteome.0c00394] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
660 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
661 Moro L. Mitochondrial DNA and MitomiR Variations in Pancreatic Cancer: Potential Diagnostic and Prognostic Biomarkers. Int J Mol Sci 2021;22:9692. [PMID: 34575852 DOI: 10.3390/ijms22189692] [Reference Citation Analysis]
662 Elamir AM, Hutchinson S, Albaba H, Keshavarzi S, Xu W, Moulton CA, McGilvary I, Cleary S, Wei A, Dodd A, Knox J, O'Kane G, Prince RM, Kalimuthu S, Kim J, Ringash J, Dawson LA, Wong R, Barry A, Brierley J, Gallinger S, Hosni A. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Clin Oncol (R Coll Radiol) 2021;33:527-35. [PMID: 33875360 DOI: 10.1016/j.clon.2021.03.007] [Reference Citation Analysis]
663 Bai RL, Wang NY, Zhao LL, Zhang YF, Cui JW. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00169-7. [PMID: 34538570 DOI: 10.1016/j.hbpd.2021.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Tao Y, Yan C, Li D, Dai J, Cheng Y, Li H, Zhu W, Guo Z. Sequence-Activated Fluorescent Nanotheranostics for Real-Time Profiling Pancreatic Cancer. JACS Au. [DOI: 10.1021/jacsau.1c00553] [Reference Citation Analysis]
665 Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.Biomedicines. 2020;8. [PMID: 33287196 DOI: 10.3390/biomedicines8120565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
666 Han H, Hou Y, Chen X, Zhang P, Kang M, Jin Q, Ji J, Gao M. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy. J Am Chem Soc 2020;142:4944-54. [PMID: 32069041 DOI: 10.1021/jacs.0c00650] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 28.5] [Reference Citation Analysis]
667 Root A. Mathematical Modeling of The Challenge to Detect Pancreatic Adenocarcinoma Early with Biomarkers. Challenges 2019;10:26. [DOI: 10.3390/challe10010026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
668 Sun H, Zhao X, Zhou Y, Wang J, Ma R, Ren X, Wang H, Zou L. Characterization of Oral Microbiome and Exploration of Potential Biomarkers in Patients with Pancreatic Cancer. Biomed Res Int 2020;2020:4712498. [PMID: 33204698 DOI: 10.1155/2020/4712498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
669 Moon HR, Ozcelikkale A, Yang Y, Elzey BD, Konieczny SF, Han B. An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations. Lab Chip 2020;20:3720-32. [PMID: 32909573 DOI: 10.1039/d0lc00707b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
670 Gupta P, Totti S, Pérez-mancera PA, Dyke E, Nisbet A, Schettino G, Webb R, Velliou EG. Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model. RSC Adv 2019;9:41649-63. [DOI: 10.1039/c9ra09123h] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
671 Drubay V, Skrypek N, Cordiez L, Vasseur R, Schulz C, Boukrout N, Duchêne B, Coppin L, Van Seuningen I, Jonckheere N. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Cancers (Basel) 2018;10:E254. [PMID: 30065235 DOI: 10.3390/cancers10080254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
672 Bradney MJ, Venis SM, Yang Y, Konieczny SF, Han B. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. Small 2020;16:e1905500. [PMID: 31997571 DOI: 10.1002/smll.201905500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
673 Xi Q, Chen Y, Yang GZ, Zhang JY, Zhang LJ, Guo XD, Zhao JY, Xue ZY, Li Y, Zhang R. miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer. Front Immunol 2020;11:890. [PMID: 32536914 DOI: 10.3389/fimmu.2020.00890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
674 Matsuura T, Maru Y, Izumiya M, Hoshi D, Kato S, Ochiai M, Hori M, Yamamoto S, Tatsuno K, Imai T, Aburatani H, Nakajima A, Hippo Y. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis. Carcinogenesis 2020;41:490-501. [PMID: 31233118 DOI: 10.1093/carcin/bgz122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
675 Lagies S, Schlimpert M, Braun LM, Kather M, Plagge J, Erbes T, Wittel UA, Kammerer B. Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. Anal Bioanal Chem 2019;411:6319-28. [PMID: 31037374 DOI: 10.1007/s00216-019-01814-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
676 Butera G, Pacchiana R, Mullappilly N, Margiotta M, Bruno S, Conti P, Riganti C, Donadelli M. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochim Biophys Acta Mol Cell Res 2018;1865:1914-23. [PMID: 30296496 DOI: 10.1016/j.bbamcr.2018.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]